

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Sex-specific Mortality Prediction by Pro-C-type Natriuretic Peptide Measurement in ST-elevation Myocardial Infarction

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048312
Article Type:	Original research
Date Submitted by the Author:	22-Dec-2020
Complete List of Authors:	Mark, Peter; Copenhagen University Hospital, Clinical Biochemistry Frydland, Martin; Copenhagen University Hospital, Cardiology Helgestad, Ole ; Odense Universitetshospital, Cardiology Holmvang, Lene; Copenhagen University Hospital, Rigshospitalet, Cardiology Møller, Jacob; Odense Universitetshospital, Department of cardiology Johansson, Pär I; Copenhagen University Hospital, Clinical Immunology Ostrowski, Sisse; Copenhagen University Hospital, Clinical Immunology Prickett, Timothy; Otago University Canterbury Medical Library, Cardiology Hassager, Christian; The University Hospital of Copenhagen, Cardiology Goetze, Jens Peter; Copenhagen University Hospital, Clinical Biochemistry
Keywords:	Myocardial infarction < CARDIOLOGY, Cardiology < INTERNAL MEDICINE, Adult cardiology < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **Sex-specific Mortality Prediction by Pro-C-type Natriuretic Peptide Measurement**
4
5
6 2 **in ST-elevation Myocardial Infarction**
7

8
9 3 Peter D. Mark, MD¹; Martin Frydland, MD²; Ole K. L. Helgestad, MD³; Lene Holmvang,
10
11 4 MD, DMSc³; Jacob E. Møller, MD, DMSc³; Pär I. Johansson, MD, DMSc⁴; Sisse R.
12
13 5 Ostrowski, MD, DMSc⁴; Timothy C. R. Prickett, PhD⁵; Christian Hassager, MD, DMSc²;
14
15 6 Jens P. Goetze, MD, DMSc^{1,6}
16
17

18
19 7 ¹Department of Clinical Biochemistry, Copenhagen University Hospital, Rigshospitalet,
20
21 8 Copenhagen, Denmark

22
23 9 ²Department of Cardiology, Copenhagen University Hospital, Rigshospitalet,
24
25 10 Copenhagen, Denmark

26
27 11 ³Department of Cardiology, Odense University Hospital, Odense, Denmark

28
29 12 ⁴Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet,
30
31 13 Copenhagen, Denmark

32
33 14 ⁵Department of Medicine, University of Otago, Christchurch, New Zealand

34
35 15 ⁶Department of Biomedical Sciences, Faculty of Health Sciences, Copenhagen
36
37 16 University, Copenhagen, Denmark
38

39 18 **Word count (Introduction to conclusion):** 3086

40
41 19 **Correspondence:** Jens P. Goetze, MD, DMSc

42
43 20 Professor, Chief Physician

44
45 21 Department of Clinical Biochemistry KB3013

46
47 22 9 Blegdamsvej, DK-2100 Copenhagen, Denmark

48
49 23 Phone: +45-3545-2202, Fax: +45-3545-2880, E-mail: JPG@dadlnet.dk

50
51
52 24 **Keywords:** Natriuretic peptides, C-type natriuretic peptide, CNP, ANP, Reference
53
54 25 intervals, Myocardial infarction.
55
56
57
58
59
60

1
2
3 1 **List of abbreviations:** CNP, C-type natriuretic peptide; ACS, acute coronary syndrome;
4
5 2 NT-proCNP, amino-terminal proCNP; STEMI, ST-elevation myocardial infarction;
6
7 3 proCNP (see Nomenclature); NOBIDA, Nordic Reference Interval Project Biobank and
8
9 4 Database; RH, Copenhagen University Hospital, Rigshospitalet; OUH, Odense
10
11 5 University Hospital; CAG, coronary angiography; ECG, electrocardiogram; BMI, body
12
13 6 mass index; LVEF, left ventricular ejection fraction; hs-CRP, high sensitivity c-reactive
14
15 7 protein; sTM, soluble thrombomodulin.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Abstract**

2 **Objective:** To determine the predictive value of pro-C-type natriuretic peptide (proCNP)
3 measurement in plasma sampled on admission from patients presenting with ST-
4 elevation myocardial infarction (STEMI).

5 **Design:** Prospective cohort study.

6 **Setting:** Two University Hospitals in Denmark.

7 **Participants:** 1760 consecutive patients (470 females and 1290 males) with confirmed
8 STEMI.

9 **Main Outcomes and Measures:** The main outcome was all-cause mortality at 30 days
10 and one year after presentation and the primary measure was proCNP concentration in
11 plasma at admission in all patients and longitudinal measurements in a consecutive
12 subgroup of 287 patients. A reference population (n = 688) defined cut-off values of
13 increased proCNP concentrations.

14 **Results:** In all patients, an increased proCNP concentration was associated with a
15 higher all-cause mortality after one year (HR: 1.6 (1.1-2.4), $P_{\text{logrank}} = .009$) including an
16 interaction of sex ($P = .03$). In separate sex-stratified analyses, female patients showed
17 increased all-cause mortality (HR_{one year}: 2.6 (1.5-4.6), $P_{\text{logrank}} < .001$), whereas no
18 differences were found in male patients (HR_{one year}: 1.1 (.7-1.9), $P_{\text{logrank}} = .66$). After
19 adjusting for potential risk factors, we found increased proCNP concentrations \geq the
20 median value to be independently associated with increased risk of mortality in female
21 patients within one year (HR per 1 pmol/L increase: 1.04 (1.01-1.06), $P = .007$).

1
2
3 1 Moreover, we found indications of sex differences in proCNP concentrations over time
4
5 2 (higher proCNP in males (4.4 (-.28 – 9.1) pmol/L, P= .07) and interaction of sex and
6
7 3 time (P= .13)), and that hypertension was independently associated with higher proCNP
8
9 4 (4.5 (.6-8.4) pmol/L, P= .03).

10
11
12
13 5 **Conclusions:** In female but not male patients presenting with STEMI, increased
14
15 6 concentrations of proCNP at admission independently indicate a higher risk of all-cause
16
17 7 mortality. The findings are remarkably specific for female patients, suggesting a different
18
19 8 vascular phenotype beyond traditional measures of coronary artery flow compared to
20
21 9 male patients.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Strengths and limitations of this study

- 2 • This is the first study to investigate the prognostic potential of measurement of
3 peptides derived from pro-C-type natriuretic peptide (proCNP) using predefined
4 sex- and age-specific cut-off values based on a reference population.
- 5 • As a novel approach, a large cohort of patients are examined during the acute
6 phase of ST-elevation myocardial infarction with plasma sampling at admission
7 and all-cause mortality within one year as main outcome.
- 8 • To clarify the temporal pattern of proCNP concentrations, longitudinal
9 measurements during admission in a subgroup of the cohort are used to further
10 examine sex differences and baseline associations.
- 11 • The sex-specific analyses are exploratory and the present report should be
12 considered a hypothesis-generating study.
- 13 • As all-cause mortality within one year is the only available outcome measure,
14 other clinical end-points and long-term follow-up is not investigated.

1 Introduction

2 C-type natriuretic peptide (CNP) is a paracrine/autocrine peptide expressed in many
3 tissues,[1] including endothelial cells.[2] Experimental studies have shown that
4 endothelial-derived CNP is locally involved in regulation of vascular tone[3,4] and
5 angiogenesis.[5] Also, a recent preclinical investigation has suggested that CNP plays a
6 key protective role in cardiac pathophysiology.[6]

7 Clinical reports on the general population as well as patients with heart disease have
8 examined circulating proCNP-derived peptides as prognostic markers.[7–9] In patients
9 presenting with acute coronary syndrome (ACS), high concentrations of amino-terminal
10 proCNP (NT-proCNP) in plasma measured 4-6 weeks after the event were reported to
11 be the only natriuretic peptide to independently predict cardiac readmission and death in
12 the patients with unstable angina.[7] Taken together, experimental and epidemiological
13 data suggest CNP to be an important regulator of cardiovascular function and that
14 increased concentrations of proCNP-derived peptides in plasma of patients reflect an
15 unfavorable cardiovascular condition. However, no large study has explored the
16 prognostic value of proCNP measurement in the acute phase of an ST-elevation
17 myocardial infarction (STEMI).[10]

18 In this study, we measured the precursor of C-type natriuretic peptides (proCNP) in
19 plasma from a large cohort of patients presenting with STEMI. We have previously
20 reported on this method for accurate quantification of “total” proCNP in plasma by a
21 processing-independent radioimmunoassay.[11] In total, 1760 patients with STEMI were
22 included, and proCNP was measured in plasma sampled at admission to determine its

1 predictive value in 30-day and one-year all-cause mortality. Moreover, we investigated a
2 subgroup of 287 patients with STEMI with longitudinal plasma samples collected during
3 the hospital admission to examine proCNP concentrations over time and further analyze
4 baseline associations between proCNP concentrations and vascular diseases. Finally,
5 we included a large sample of healthy individuals (n = 688) in order to, independently of
6 the patient cohort, establish age- and sex-specific reference intervals for proCNP
7 concentrations in plasma.

8 *Nomenclature*

9 ProCNP: In the present article, proCNP refers to a specific amino-acid sequence
10 (human proCNP 11-27) within the prohormone sequence of CNP; the epitope of the
11 antiserum of our radioimmunoassay. In this processing-independent methodology, we
12 utilize this fragment after enzymatic cleavage in vitro as a proxy measure of all proforms
13 released to plasma irrespective of prohormone post-translational processing.

14 ProCNP-derived peptides: Collective term for any fragment of the prohormone of CNP.

15 **Methods**

16 REFERENCE POPULATION

17 For establishment of reference intervals, we used plasma samples from the Nordic
18 Reference Interval Project Biobank and Database (NOBIDA), originally consisting of
19 3002 subjects.[12] A subgroup of 853 subjects from this population was randomly
20 selected with the aim to represent sex, age, and country of origin equally, as previously
21 described.[13]

1 COHORT OF PATIENTS WITH STEMI

2 Patients with suspected STEMI were consecutively included from two Danish hospitals
3 over a period of one year (2015/2016) (Copenhagen University Hospital, Rigshospitalet
4 (RH), and Odense University Hospital (OUH)). The procedure of inclusion has been
5 described previously.[14] From this cohort of patients with suspected STEMI and triaged
6 for acute coronary angiography (CAG) (based on assessment of symptoms and the
7 individual electrocardiogram (ECG)), we only included patients with confirmed
8 STEMI.[15] All patients underwent CAG (See further details on data collection in the
9 Supplemental Material).

10 PATIENT AND PUBLIC INVOLVEMENT

11 Patients and/or the public were not involved in the design, or conduct, or reporting, or
12 dissemination plans of this research.

13 ETHICS

14 Patients gave written informed consent. When patients were not able to provide this
15 (e.g. comatose cardiac arrest patients), consent was obtained by the patients' next of
16 kin and general practitioners in accordance with national legislation. The study was
17 approved by the local ethics committee (Copenhagen) (Ref. H-2-2014-110).

18 BIOCHEMICAL ANALYSES

19 Plasma proANP and proCNP concentrations were quantified by the previously reported
20 processing-independent assay technology and procedures.[11,16,17] Information of
21 other biochemical analyses can be found in the Supplemental Material.

1 ALL-CAUSE MORTALITY

2 The Danish Civil Registration System was used for all-cause mortality assessment. All
3 Danish citizens are recorded with a unique 10-digit civil registration number, and deaths
4 are registered within 2 weeks. Initial follow-up began on the date of admission and
5 continued until date of death, or October 30th, 2017.

6 STATISTICS

7 *Reference Population*

8 We divided the reference population into groups based on sex and age (<50 and ≥50
9 years) and used the RefVal software[18] to calculate 95% reference intervals based on
10 a non-parametric bootstrapping method.

11 *STEMI Cohort*

12 Based on their respective sex- and age-specific reference interval from the reference
13 population, all STEMI patients were stratified according to a) increased proCNP
14 concentration (higher than the 95% reference interval), b) normal proCNP concentration
15 (within the 95% reference interval), and c) decreased proCNP concentration (lower than
16 the 95% reference interval). Dichotomous variables are presented as numbers (n) and
17 percentages (%). Continuous variables are presented as medians with 25th–75th
18 percentiles. Comparisons between groups were done using independent non-
19 parametric t-tests and Fisher's exact two-sided test. Spearman's correlation analyses
20 were used to assess the relationships between proCNP and other biochemical analytes.
21 Differences in median proCNP concentrations at different time intervals from onset of

1 symptoms to blood sample were assessed by Kruskal-Wallis tests (this time parameter
2 also reflects total ischemic time; see Supplemental Material). All-cause mortality after 30
3 days and one year was assessed in patients stratified into normal or increased proCNP
4 concentrations and depicted by Kaplan-Meier plots and then compared with the log-rank
5 test and estimates of hazard ratio including 95% confidence intervals. We performed a
6 statistic test of interaction between sex and groups of proCNP. To test the relation of
7 mortality and proCNP concentrations on a continuous scale, we performed cubic spline
8 plots with the density distribution and the logarithm of hazard ratios. We focused our
9 further mortality analyses on proCNP concentrations \geq median, where we observed an
10 effect of increasing proCNP concentrations on mortality. Patients were divided into
11 groups of \geq vs. $<$ median proCNP according to sex- and age-specific median proCNP
12 concentrations in the reference population. Multivariable Cox proportional hazard
13 models including proCNP, age, plasma creatinine, plasma proANP, time from onset of
14 symptoms to blood sample, number of coronary vessels affected and tertiles of peak
15 plasma troponin concentrations were constructed for mortality assessment. Both
16 plasma proANP and creatinine were logarithmically transformed, where peak troponin T
17 and troponin I were combined in one variable of tertiles (represented by values of one to
18 three) as a proxy myocardial infarction size, before being entered into the model. For
19 longitudinal analyses, we constructed four time points/intervals for statistical analyses
20 (1: samples from admission; 2: 1 to 12 hours after admission; 3: >12 to 24 hours after
21 admission; 4: >24 hours after admission). We used linear mixed models of unstructured
22 co-variances to examine changes in concentrations and associations with co-variables
23 over time. Statistical analyses were performed using RefVal software²⁰ for calculation of

1
2
3 1 reference intervals, statistical software R version 3.6.1 (R Core Team, Vienna,
4
5 2 Austria[19]) for linear mixed models (nlme package), and IBM SPSS Statistics 22
6
7 3 (SPSS Inc., Chicago, Illinois, United States) for other analyses. A *P*-value <.05 was
8
9 4 considered statistically significant.

13 **Results**

16 6 In the NOBIDA reference population, we measured proCNP concentrations in available
17
18 7 plasma from 688 subjects (358 females; 330 males). From these measurements, 95%
19
20 8 reference intervals for females vs. males and < vs. ≥ 50 years were calculated (see
21
22 9 results in the Supplemental Material).

26 10 From the cohort of 2247 patients with suspected STEMI, 1760 patients (460
27
28 11 females and 1290 males) with verified STEMI and available plasma were included in
29
30 12 our study (see Supplemental Material for histograms of the distribution of plasma
31
32 13 proCNP concentrations in the reference population). When compared to the sex- and
33
34 14 age-specific reference intervals, a total of 283 (16.1%) of the patients had an increased
35
36 15 proCNP concentration; no difference in sex-specific proportions was observed (*P* = .42).

41 16 Table 1 shows the baseline characteristics and follow-up in patient groups
42
43 17 defined by normal or increased proCNP concentrations. Five patients (one male and
44
45 18 four females) displayed decreased proCNP concentrations and were not included in
46
47 19 Table 1. Missing individual information on each variable in each group was between
48
49 20 .1% and 4.4%, except for age, sex, mortality, cardiogenic shock, cardiac arrest coma,
50
51 21 time from onset of symptoms to blood sample, and TIMI grade flow, where information
52
53 22 from all patients was available. Female patients with increased proCNP concentrations
54
55
56
57
58
59
60

1 at admission had a higher prevalence of hypertension ($P = .003$), diabetes mellitus ($P =$
2 $.022$), peripheral artery disease ($P = .002$), and kidney disease ($P < .001$), whereas
3 male patients had higher prevalence of hypertension ($P = .004$), stroke ($P = .012$), and
4 kidney disease ($P < .001$). Increased proCNP was associated with higher
5 concentrations of proANP ($P = .019$) and soluble thrombomodulin (sTM) ($P = .001$) in
6 female patients and with higher concentrations of creatinine ($P < .001$), syndecan-1 ($P =$
7 $.019$), and sTM ($P = .003$) in male patients. Lastly, we found a higher one-year mortality
8 rate ($P = .001$) and prevalence of cardiogenic shock development ($P = .013$) in female
9 patients with increased proCNP concentrations, whereas no differences were found in
10 male patients. For biochemical markers with positive associations to proCNP, we
11 performed Spearman's correlation analyses (see the Supplemental Material for results).

12 Thirty-days and one-year all-cause mortality plots of normal and increased
13 proCNP concentrations of all patients and stratified by sex are depicted in Figure 1.
14 Different mortality rates were found for all patients at both time points ($HR_{30 \text{ days}} = 1.6$
15 $(1.0-2.6)$, $P_{logrank} = .03$ and $HR_{one-year} = 1.6 (1.1-2.4)$, $P_{logrank} = .009$). However, we found
16 an interaction of sex and groups of proCNP ($P = .03$). In sex-specific estimates, only
17 female patients showed different mortality rates (females_{30 days}: $HR = 2.8 (1.4-5.6)$,
18 $P_{logrank} = .002$, females_{one-year}: $HR = 2.6 (1.5-4.6)$, $P_{logrank} < .001$, males_{30 days}: $HR = 1.1$
19 $(0.6-2.1)$, $P_{logrank} = .87$, and males_{one-year}: $HR = 1.1 (.7-1.9)$, $P_{logrank} = .66$). In cubic spline
20 plots, we observed an effect of increasing proCNP as a continuous variable on mortality
21 from median concentrations in both sexes. We therefore focused on this upper range of
22 proCNP concentrations in Cox regression analyses (see Supplemental Figure 3). In a
23 univariate Cox proportional hazard model, we found an elevated hazard ratio (HR) of

1 all-cause mortality with increases of plasma proCNP for both sexes (results shown in
2 Table 2). When including age and plasma creatinine in a multivariable model (Model 1),
3 proCNP was independently associated with mortality in female but not in male patients
4 (see Table 2): HR (95% CI) for female patients was 1.04 (1.01-1.07) ($P = .008$) for 30-
5 day and 1.03 (1.01-1.06) ($P = .010$) for one-year mortality, whereas HR was 1.00 for
6 both all patients and male patients at both time points (see Table 2). In a model where
7 proANP, tertiles of peak troponins, number of vessels affected, and time from onset of
8 symptoms to admission were also added (Model 2), risk estimates of proCNP (per one
9 pmol/L increase) were: HR (95% CI) = 1.04 (1.01-1.07), $P = .016$ for 30-day mortality,
10 and HR (95% CI) = 1.04 (1.01-1.06), $P = .007$ for one-year mortality.

11 To examine proCNP concentrations over time during a STEMI and further test
12 the baseline associations of vascular disease and increased proCNP, we used a set of
13 longitudinal plasma samples from a consecutive subgroup of the cohort consisting of
14 287 STEMI patients (64 females and 223 males). Results are shown in Figure 2 and
15 Table 3. An overall decrease in proCNP concentration was estimated to be 3.8 pmol/L
16 (~10%) ($P = .001$) from admission to >24 hours. In a multivariate model including sex,
17 age, and chronic diseases (Model 3), kidney disease and hypertension were
18 independently associated with higher concentrations of proCNP ($P < .001$ and $P = .03$,
19 respectively), whereas time and age were not independently associated with changes in
20 proCNP. Also, both Model 2 and 3 implied a positive association of proCNP
21 concentration and male sex, and an interaction of time and sex; however, the statistical
22 uncertainty of these estimates was substantial ($P = .07$ and $P = .13$, respectively).
23 Figure 2 shows proCNP concentrations over time in overall and sex-specific graphs

1
2
3 1 including graphs of kidney disease and hypertension (see the Supplemental Material for
4
5 2 further results of longitudinal measurements).
6
7

8 3 **Discussion**

9
10
11 4 In this study, we report on a marked sex-specific prognostic information profile for
12
13 5 proCNP measurement in patients presenting with a STEMI. A major advantage of our
14
15 6 present approach comes from an independent establishment of a sex-specific proCNP
16
17 7 reference interval prior to patient measurement. This allowed us to perform clinically
18
19 8 meaningful divisions of normal, decreased, or increased proCNP concentrations in
20
21 9 plasma specific to sex, rather than testing differences only within the patient cohort as a
22
23 10 whole (see the Supplemental Material for discussion of age groups).
24
25
26
27

28
29 11 In this cohort of consecutive patients with a verified STEMI, we show that 16.1%
30
31 12 have increased concentrations of proCNP during the early phase of the myocardial
32
33 13 infarction compared with the sex- and age-specific intervals. Interestingly, besides
34
35 14 higher prevalence of kidney disease, we found a markedly higher prevalence of
36
37 15 cardiovascular disease including hypertension in both sexes; diabetes mellitus and
38
39 16 peripheral artery disease for female patients; and stroke for males among patients with
40
41 17 increased proCNP. Our longitudinal analyses of a subgroup of the STEMI patients
42
43 18 corroborates that the association to both kidney disease and hypertension is consistent
44
45 19 even over time and is independent of sex, age, and other cardiovascular diseases. A
46
47 20 putative explanation for the linkage of hypertension and increased proCNP
48
49 21 concentrations is the upregulation of CNP expression by vascular shear stress.[20,21]
50
51
52 22 The positive association of proCNP and a vascular marker, sTM, for both sexes also
53
54
55
56
57
58
59
60

1 support the relation of circulating proCNP with vascular stress. In contrast, the baseline
2 associations of increased proCNP concentrations and diabetes, peripheral artery
3 disease and stroke, respectively, are not statistically independent in longitudinal
4 analyses. However, given the sex-specific pattern in the baseline findings and the
5 limited number of patients with the respective diseases in longitudinal analyses, the
6 results may be too preliminary to sufficiently conclude on the potential associations to
7 diabetes, peripheral artery disease, and stroke. Also, the statistical uncertainty of the
8 suggested effect of sex and interaction of sex and time in longitudinal analyses calls for
9 a cautious interpretation (see the Supplemental Material for further discussion of
10 longitudinal analyses).

11 The risks of death within 30 days and one year were higher for female patients
12 with increased proCNP concentrations – but not for male patients. This marked sex-
13 specific association was confirmed when the mortality rate was analyzed by increases
14 of proCNP \geq median, where proCNP proved to be an independent predictor in a model
15 (Model 1 in Table 2) including two additional variables, age and plasma creatinine,
16 which have previously established associations with NT-proCNP in plasma.[22] To
17 further test the prognostic potential of proCNP, we added plasma proANP, tertiles of
18 peak troponins, number of vessels affected, and time from onset of symptoms to
19 admission into a multivariable model (Model 2). In this model, increases of proCNP
20 were still independently associated with the risk of death, and the estimates were of
21 similar size at both time points. Recent data on patients with STEMI found no
22 independent prognostic value on mortality rate for NT-proCNP concentrations.[7]
23 However, that report differed from ours in several aspects including radioimmunoassay

1 principle and duration of follow-up, and, importantly, plasma was sampled 4-6 weeks
2 after admission in contrast to our real-time STEMI investigation. These differences
3 make a direct comparison difficult.

4 Our results firmly suggest a sex-specific association with survival, where
5 increased proCNP concentrations indicate a poorer prognosis in female patients.
6 Previously, studies have shown that CNP acts as a more potent vasodilator in female
7 porcine arteries[23] and that the female sex hormone estradiol upregulates the
8 expression of CNP in vascular endothelial cells.[24] Furthermore, recent preclinical
9 reports have convincingly pointed to a pivotal role of CNP and its receptors in the
10 regulation of the microcirculation[4] and in cardiac homeostasis.[25] Taken together,
11 these previous findings suggest that the CNP system is a critical modulator of vascular
12 integrity and function including a more pronounced vasodilatory capacity in females that
13 may be provided by female sex hormones. Clinical evidence shows that females display
14 a sharp rise in the incidence of cardiovascular disease after menopause and that
15 changes in sex hormones by complex mechanisms play a key role in the loss of
16 vasoprotection.[26,27] Notably, postmenopausal females are at higher risk of coronary
17 microvascular dysfunction and HFpEF compared with their male counterparts,[28] and
18 high concentrations of NT-proCNP have previously been independently linked to an
19 adverse outcome in patients with HFpEF.[8] In this perspective, we speculate that our
20 observed sex-specific effect of increased proCNP concentrations in plasma of patients
21 with STEMI partly reflects ongoing vascular dysfunction in females in particular and,
22 hence, represents an independent signal of poor cardiovascular prognosis. However,

1
2
3 1 there is a need for translational research to elucidate this association between
4
5 2 increased proCNP in females with vascular complications and increased mortality rate.
6
7

8 3 *Limitations*

9

10
11 4 While the number of patients with STEMI in the cohort is high, the follow-up period is
12
13 5 relatively short. We examined only all-cause mortality as outcome in our follow-up
14
15 6 multivariable Cox regression analyses, and other clinical endpoints, e.g., cardiac
16
17 7 readmission, were not tested. Hence, the number of events limits the number of
18
19 8 possible covariates in the multivariable Cox regression analyses (Model 3), and sex-
20
21 9 specific estimates of 30-day mortality in this model should be interpreted cautiously.
22
23 10 Moreover, this study focused on increased proCNP and the upper range of proCNP
24
25 11 concentrations in plasma, whereas associations of decreased proCNP concentrations
26
27 12 were not investigated. With regard to measurement of troponins in plasma, two different
28
29 13 analytes (TnT and TnI) were measured at the two hospitals of inclusion. Thus, a
30
31 14 combined variable of tertiles of peak troponins (discrete values of one to three) was
32
33 15 included in the multivariable models with less quantitative information than the
34
35 16 measured concentrations. Baseline biochemical analyses were performed on arterial
36
37 17 plasma, whereas venous plasma was used from the reference population and in
38
39 18 repeated measurements. A previous report has shown slightly lower plasma
40
41 19 concentrations of NT-proCNP in arterial compared with venous plasma.[29] Thus, in
42
43 20 theory, our approach will underestimate the proportion of STEMI patients with increased
44
45 21 proCNP concentration and the initial longitudinal decrease in proCNP concentration
46
47 22 from baseline to the second time point (0 to 1-12 hours).
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Conclusions**

2 We show here that increased proCNP concentrations in plasma from patients
3 presenting with STEMI are associated with a higher all-cause mortality rate within one
4 year among female patients with STEMI, whereas male patients display no such
5 pattern. Moreover, we report that an increase of proCNP in the upper range of plasma
6 concentrations in female patients is an independent prognostic marker of mortality at
7 both 30 days and one year. The findings are remarkably specific for female patients,
8 suggesting a different vascular phenotype beyond traditional measures of coronary
9 artery flow compared to male patients.

1 **Acknowledgements**

2 We are grateful to laboratory technicians Marie Ziebell Severinsen and Anne Truesen
3 Asanovski for their expertise regarding proANP and proCNP measurement in plasma.

4 **Contributors**

5 Designed the study: PDM, MF, CH, JPG. Designed and conducted the STEMI cohort
6 study: MF, OKLH, LH, JEM, CH. Undertook biochemical measurements: PDM, SRO,
7 PIJ, JPG. Performed the data analysis: PDM, MF, TCRP. Wrote the manuscript draft:
8 PDM. Revised the paper based on intellectual contribution: PDM, MF, OKLH, LH, JEM,
9 PIJ, SRO, TCRP, CH, JPG.

10 **Funding**

11 Research grants from Rigshospitalet.

12 **Competing interests**

13 None to report.

14 **Patient and public involvement**

15 Patients and/or the public were not involved in the design, or conduct, or reporting, or
16 dissemination plans of this research.

17 **Ethics approval**

18 The study was approved by the local ethics committee (Copenhagen) (Ref. H-2-2014-
19 110).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Data availability statement**

2 Data are available upon reasonable request (email: JPG@dadlnet.dk).

For peer review only

1 References

- 2 1 Sellitti DF, Koles N, Mendona MC. Regulation of C-type natriuretic peptide
3 expression. *Peptides*. 2011;**32**:1964–71. doi:10.1016/j.peptides.2011.07.013
- 4 2 Stingo AJ, Clavell AL, Heublein DM, *et al*. Presence of C-type natriuretic peptide
5 in cultured human endothelial cells and plasma. *Am J Physiol - Hear Circ Physiol*
6 1992;**263**:H1318-21. doi:10.1152/ajpheart.1992.263.4.h1318
- 7 3 Nakao K, Kuwahara K, Nishikimi T, *et al*. Endothelium-Derived C-Type Natriuretic
8 Peptide Contributes to Blood Pressure Regulation by Maintaining Endothelial
9 Integrity. *Hypertension* 2017;**69**:286–96.
10 doi:10.1161/HYPERTENSIONAHA.116.08219
- 11 4 Špiranec K, Chen W, Werner F, *et al*. Endothelial C-type natriuretic peptide acts
12 on pericytes to regulate microcirculatory flow and blood pressure. *Circulation*
13 2018;**138**:494–508. doi:10.1161/CIRCULATIONAHA.117.033383
- 14 5 Bubb KJ, Aubdool AA, Moyes AJ, *et al*. Endothelial C-Type Natriuretic Peptide Is
15 a Critical Regulator of Angiogenesis and Vascular Remodeling. *Circulation*
16 2019;**139**:1612–28. doi:10.1161/CIRCULATIONAHA.118.036344
- 17 6 Parmar KM, Larman HB, Dai G, *et al*. Integration of flow-dependent endothelial
18 phenotypes by Kruppel-like factor 2. *J Clin Invest* 2006;**116**:49–58.
19 doi:10.1172/JCI24787
- 20 7 Prickett TCR, Doughty RN, Troughton RW, *et al*. C-type natriuretic peptides in
21 coronary disease. *Clin Chem* 2017;**63**:316–24.

- 1
2
3 1 doi:10.1373/clinchem.2016.257816
4
5
6 2 8 Lok DJ, Klip IJT, Voors AA, *et al.* Prognostic value of N-terminal pro C-type
7
8 natriuretic peptide in heart failure patients with preserved and reduced ejection
9 3
10 fraction. *Eur J Heart Fail* 2014;**16**:958–66. doi:10.1002/ejhf.140
11 4
12
13
14 5 9 Sangaralingham SJ, McKie PM, Ichiki T, *et al.* Circulating C-Type Natriuretic
15
16 Peptide and Its Relationship to Cardiovascular Disease in the General Population.
17 6
18 *Hypertension* 2015;**65**:1187–94. doi:10.1161/HYPERTENSIONAHA.115.05366
19 7
20
21
22 8 10 Pemberton CJ, Siriwardena M, Kleffmann T, *et al.* C-type natriuretic peptide
23
24 (CNP) signal peptide fragments are present in the human circulation. *Biochem*
25
26 *Biophys Res Commun* 2014;**449**:301–6. doi:10.1016/j.bbrc.2014.05.020
27 10
28
29
30 11 11 Lippert SK, Rehfeld JF, Goetze JP. Processing-independent analysis for pro-C-
31
32 type natriuretic peptide. *J Immunol Methods* 2010;**362**:32–7.
33
34 13 doi:10.1016/j.jim.2010.08.003
35
36
37 14 12 Felding P, Rustad P, Mårtensson A, *et al.* Reference individuals, blood collection,
38
39 treatment of samples and descriptive data from the questionnaire in the Nordic
40 15
41 Reference Interval Project 2000. *Scand J Clin Lab Invest* 2004;**64**:327–42.
42 16
43
44 17 doi:10.1080/00365510410006630
45
46
47 18 13 Mark PD, Hunter I, Terzic D, *et al.* Processing-independent proANP measurement
48
49 for low concentrations in plasma: Reference intervals and effect of body mass
50 19
51 index and plasma glucose. *Clin Chem Lab Med* 2017;**56**:132–7.
52 20
53
54 21 doi:10.1515/cclm-2017-0309
55
56
57
58
59
60

- 1
2
3 1 14 Obling L, Frydland M, Hansen R, *et al*. Risk factors of late cardiogenic shock and
4 mortality in ST-segment elevation myocardial infarction patients. *Eur Hear journal*
5
6 2
7
8 3 *Acute Cardiovasc care* 2018;**7**:7–15. doi:10.1177/2048872617706503
9
10
11 4 15 Thygesen K, Alpert JS, Jaffe AS, *et al*. Third universal definition of myocardial
12 infarction. *Circulation* 2012;**126**:2020–35. doi:10.1161/CIR.0b013e31826e1058
13
14
15
16 6 16 Rehfeld J, Goetze J. The Posttranslational Phase of Gene Expression: New
17 Possibilities in Molecular Diagnosis. *Curr Mol Med* 2005;**3**:25–38.
18
19 7
20 doi:10.2174/1566524033361717
21
22
23
24 9 17 Hunter I, Rehfeld JF, Goetze JP. Measurement of the total proANP product in
25 mammals by processing independent analysis. *J Immunol Methods*
26
27 10
28 2011;**370**:104–10. doi:10.1016/j.jim.2011.06.005
29
30
31
32 12 18 Solberg HE. The IFCC recommendation on estimation of reference intervals. The
33 RefVal program. *Clin Chem Lab Med* 2004;**42**:710–4.
34
35 13
36 14 doi:10.1515/CCLM.2004.121
37
38
39
40 15 19 3.5.1. RDCT. A Language and Environment for Statistical Computing. *R Found*
41 *Stat Comput* 2018;**2**:<https://www.R-project.org>.<http://www.r-project.org>
42
43
44
45 17 20 Chun TH, Itoh H, Ogawa Y, *et al*. Shear stress augments expression of C-type
46 natriuretic peptide and adrenomedullin. *Hypertension* 1997;**29**:1296–302.
47
48 18
49 19 doi:10.1161/01.HYP.29.6.1296
50
51
52
53 20 21 Zhang Z, Xiao Z, Diamond SL. Shear Stress Induction of C-type Natriuretic
54 Peptide (CNP) in Endothelial Cells is Independent of NO Autocrine Signaling. *Ann*
55
56
57
58
59
60

- 1
2
3 1 *Biomed Eng* 1999;**27**:419–26. doi:10.1114/1.203
4
5
6 2 22 Prickett TCR, Olney RC, Cameron VA, *et al.* Impact of age, phenotype and
7
8 cardio-renal function on plasma C-type and B-type natriuretic peptide forms in an
9 3
10 adult population. *Clin Endocrinol (Oxf)* 2013;**78**:783–9. doi:10.1111/cen.12035
11 4
12
13
14 5 23 Barber DA, Burnett JC, Fitzpatrick LA, *et al.* Gender and relaxation to C-type
15
16 natriuretic peptide in porcine coronary arteries. *J Cardiovasc Pharmacol*
17 6
18 1998;**32**:5–11. doi:10.1097/00005344-199807000-00002
19 7
20
21
22 8 24 Prickett TCR, Barrell GK, Wellby M, *et al.* Effect of sex steroids on plasma C-type
23
24 natriuretic peptide forms: Stimulation by oestradiol in lambs and adult sheep. *J*
25 9
26 *Endocrinol* 2008;**199**:481–7. doi:10.1677/JOE-08-0267
27 10
28
29
30 11 25 Moyes AJ, Chu SM, Aubdool AA, *et al.* C-type natriuretic peptide co-ordinates
31
32 cardiac structure and function. *Eur Heart J* 2020;**41**:1006–20.
33
34 12
35 doi:10.1093/eurheartj/ehz093
36
37
38 14 26 Vitale C, Mendelsohn ME, Rosano GMC. Gender differences in the
39
40 cardiovascular effect of sex hormones. *Nat Rev Cardiol* 2009;**6**:532–42.
41
42 15
43 doi:10.1038/nrcardio.2009.105
44
45
46 17 27 Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender
47
48 differences. *Science (80-)* 2005;**308**:1583–7. doi:10.1126/science.1112062
49
50
51 19 28 Den Ruijter HM, Haitjema S, Asselbergs FW, *et al.* Sex matters to the heart: A
52
53 special issue dedicated to the impact of sex related differences of cardiovascular
54
55 20
56 diseases. *Atherosclerosis* 2015;**241**:205–7.
57
58
59
60

1
2
3 1 doi:10.1016/j.atherosclerosis.2015.05.003
4
5

6 2 29 Palmer SC, Prickett TCR, Espiner EA, *et al.* Regional release and clearance of C-
7
8 type natriuretic peptides in the human circulation and relation to cardiac function.
9 3
10
11 4 *Hypertension* 2009;**54**:612–8. doi:10.1161/HYPERTENSIONAHA.109.135608
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Sex-specific characteristics, medical history, and biochemical results in groups of proCNP concentrations in the STEMI-cohort.

	All patients (n = 1755)			Females (n = 466)			Males (n = 1289)		
	Normal proCNP	Increased proCNP	P Value	Normal proCNP	Increased proCNP	P Value	Normal proCNP	Increased proCNP	P Value
Number, n (%)	1472 (83.6)	283 (16.1)	-	385 (81.9)	81 (17.2)	-	1087 (84.2)	202 (15.6)	-
Age, years	63 (54-72)	66 (56-76)	.046	67 (56-77)	72 (60-80)	.16	62 (53-70)	64 (55-74)	.21
Males, n (%)	1087 (73.8)	202 (71.4)	.42	-	-	-	-	-	-
Height, cm	-	-	-	165 (160-169)	164 (160-168)	.13	178 (173-182)	178 (174-183)	.87
BMI, kg/m²	26.3 (24.1-29.3)	26.3 (23.8-30.1)	.96	25.4 (20.0-29.1)	25.7 (22.5-31.2)	.61	26.5 (24.5-29.3)	26.5 (24.2-29.9)	.76
Smoking, n (%)	1045 (73.3)	203 (74.9)	.60	250 (68.1)	54 (70.1)	.79	795 (75.1)	149 (76.8)	.65
Time from symptom to blood sample, min	190 (128-376)	178 (125-292)	.34	210 (136-460)	216 (141-349)	>.99	185 (125-356)	167 (123-271)	.18
LVEF, %	45 (40-55)	45 (35-55)	.33	50 (40-55)	45 (35-55)	.62	45 (40-55)	45 (36-55)	.36
Culprit vessel									
None, n (%)	55 (3.7)	7 (2.5)	.38	21 (5.5)	5 (6.2)	.79	34 (3.1)	2 (1.0)	.10
Left main coronary artery, n (%)	31 (2.1)	5 (1.8)	>.99	15 (3.9)	2 (2.5)	.75	16 (1.5)	3 (1.5)	>.99
Left anterior descending coronary artery, n (%)	623 (42.3)	119 (42.0)	.95	144 (37.4)	31 (38.3)	.90	479 (44.1)	88 (43.6)	.94
Right coronary artery, n (%)	529 (35.9)	115 (40.6)	.14	148 (38.4)	34 (42.0)	.62	381 (35.1)	81 (40.1)	.18
Left circumflex, n (%)	221 (15.0)	36 (12.7)	.36	54 (14.0)	9 (11.1)	.59	167 (15.4)	27 (13.4)	.52
Graft, n (%)	10 (0.7)	1 (0.4)	>.99	1 (0.3)	0 (0)	>.99	9 (0.8)	1 (0.5)	>.99
Number of vessels affected									
No-vessel disease, n (%)	29 (2.0)	2 (0.7)	.21	14 (3.6)	2 (2.5)	>.99	15 (1.4)	0 (0)	.15
One-vessel disease, n (%)	903 (61.5)	172 (60.7)	.84	243 (63.4)	46 (56.8)	.31	660 (60.8)	126 (62.4)	.70
Two-vessels disease, n (%)	333 (22.7)	61 (21.6)	.76	75 (19.6)	20 (24.7)	.29	258 (23.8)	41 (20.3)	.32
Three-vessels disease, n (%)	204 (13.9)	48 (17.0)	.20	51 (13.3)	13 (16.0)	.48	153 (14.1)	35 (17.3)	.23
Thrombolysis in Myocardial Infarction (TIMI) grade flow									
0, n (%)	96 (6.8)	21 (7.4)	.60	28 (7.2)	8 (9.9)	.49	68 (6.3)	13 (6.4)	.88
1, n (%)	6 (0.4)	1 (0.4)	>.99	1 (0.3)	0 (0)	>.99	5 (0.5)	1 (0.5)	>.99
2, n (%)	49 (3.3)	7 (2.5)	.58	17 (4.4)	2 (2.5)	.55	32 (2.9)	5 (2.5)	>.99
3, n (%)	1321 (89.7)	254 (89.8)	>.99	339 (88.1)	71 (87.7)	.85	982 (90.3)	183 (90.6)	>.99
Medical history, n (%)									

Hypertension	612 (42.6)	156 (56.1)	<.001	177 (46.9)	52 (65.8)	.003	435 (41.0)	104 (52.3)	.004
Diabetes mellitus	177 (12.3)	51 (18.3)	.009	47 (12.5)	18 (22.2)	.022	130 (12.2)	33 (16.5)	.11
Peripheral artery disease	72 (5.0)	24 (8.5)	.023	15 (4.0)	11 (13.6)	.002	57 (5.3)	13 (6.4)	.50
Stroke	91 (6.3)	30 (10.6)	.015	30 (7.9)	8 (9.9)	.51	61 (5.7)	22 (10.9)	.012
Kidney disease	41 (2.8)	40 (14.1)	<.001	10 (2.6)	11 (13.6)	<.001	31 (2.9)	29 (14.4)	<.001
Ischemic heart disease	218 (14.8)	43 (16.3)	.53	44 (11.5)	10 (12.3)	.85	174 (16.0)	36 (17.9)	.53
Heart failure	38 (2.6)	13 (4.6)	.079	6 (1.6)	3 (3.7)	.19	32 (2.9)	10 (5.0)	.13
Biochemical analyses									
Acute Troponin I, ng/L	220 (53-1576)	323 (86-887)	.52	293 (54-3220)	813 (176-1814)	.57	188 (53-1481)	211 (58-844)	.99
Acute Troponin T, ng/L	1610 (329-3940)	953 (222-3370)	.018	1520 (394-3540)	571 (166-2753)	.076	1640 (287-4058)	1250 (242-3710)	.24
Peak Troponin I, ng/L	20264 (3413-50000)	19981 (5508-50000)	.91	12970 (2734-41856)	11721 (4014-50000)	.98	24507 (3654-50000)	20575 (5771-47927)	.56
Peak Troponin T, ng/L	3110 (1230-6920)	2430 (880-8060)	.23	2520 (995-5930)	2290 (614-8123)	.55	3380 (1400-7603)	2860 (923-8075)	.23
Plasma creatinine, $\mu\text{mol/L}$	81 (70-96)	95 (80-126)	<.001	69 (59-84)	83 (63-113)	.072	85 (74-98)	97 (86-131)	<.001
proANP, pmol/L	822 (515-1315)	1005 (558-1742)	.005	978 (664-1504)	1382 (747-2064)	.019	758 (488-1241)	899 (508-1499)	.10
hs-CRP ≥ 2 mg/L, n (%) *, †	474 (65.0)	111 (63.1)	.66	117 (67.2)	34 (68.0)	>.99	357 (64.3)	77 (61.1)	.54
ST2, ng/ml	40.0 (29.1-56.8)	39.8 (30.4-59.7)	.95	35.3 (27.0-55.0)	34.8 (26.2-58.4)	.92	41.5 (30.2-57.5)	41.5 (32.1-60.0)	.95
Syndecan-1, ng/ml^b	92.3 (64.2-137.0)	103.5 (69.4-154.0)	.001	82.2 (52.5-137.3)	99.3 (61.8-140.8)	.21	94.4 (68.1-137.0)	113.5 (71.6-155.1)	.019
Soluble thrombomodulin, ng/ml^b	7.35 (5.98-8.91)	8.49 (6.67-10.86)	<.001	6.71 (5.42-8.15)	8.05 (6.16-10.80)	.001	7.57 (6.19-9.18)	8.53 (6.70-10.87)	.003
Follow-up, n (%)									
Number of deaths within one year	114 (7.7%)	35 (12.4%)	.014	37 (9.6%)	19 (23.5%)	.001	77 (7.1%)	16 (7.9%)	.66
Cardiogenic shock	122 (8.3%)	34 (12.0%)	.052	32 (8.3%)	15 (18.5%)	.013	90 (8.3%)	19 (9.4%)	.58
Cardiac arrest coma	66 (4.5%)	19 (6.7%)	.13	14 (3.6%)	3 (3.7%)	>.99	52 (4.8%)	16 (7.9%)	.084

Continuous variables are given in median (inter-quartile range).

* Only patients with a time from onset of symptoms to CAG of <6 hours were included.

† Only patients admitted at RH (313 females and 873 males) were included.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 2. Cox regression analyses of mortality in patients with proCNP ≥ median.

		Univariate			Model 1*			Model 2 †		
		HR	95% CI	P Value	HR	95% CI	P Value	HR	95% CI	P Value
All patients with proCNP ≥ median (n = 928)										
ProCNP (per 1 pmol/L increase)	30-day mortality	1.02	1.01-1.03	<.001	1.00	0.99-1.01	.89	1.00	0.99-1.02	.57
	1-year mortality	1.02	1.01-1.03	<.001	1.00	0.99-1.01	.89	1.00	0.99-1.02	.58
Females with proCNP ≥ median (n=260)										
ProCNP (per 1 pmol/L increase)	30-day mortality	1.05	1.02-1.07	<.001	1.04	1.01-1.07	.008	1.04	1.01-1.07	.016
	1-year mortality	1.04	1.02-1.07	<.001	1.03	1.01-1.06	.010	1.04	1.01-1.06	.007
Males with a proCNP ≥ median (n = 668)										
ProCNP (per 1 pmol/L increase)	30-day mortality	1.02	1.01-1.03	.001	1.00	0.98-1.02	.86	1.00	0.98-1.02	.92
	1-year mortality	1.02	1.01-1.03	<.001	1.00	0.98-1.01	.72	1.00	0.98-1.02	.86

* Multivariable model with age and plasma creatinine included as co-variables.

† Multivariable model with age, plasma creatinine, proANP, tertiles of peak troponins, number of vessels affected, and time from onset of symptoms to blood sample included as co-variables.

HR, hazard ratio; CI, confidence interval.

Table 3: Linear mixed models of longitudinal measurements of proCNP in 287 patients with STEMI.

	<i>Univariate</i>		<i>Model 1</i>		<i>Model 2</i>	
	Value (95% CI) / pmol/L	<i>P</i> Value	Value (95% CI) / pmol/L	<i>P</i> Value	Value (95% CI) / pmol/L	<i>P</i> Value
Time (per time point)	-1.3 (-2.1 – -0.5)	.001	-0.25 (-1.8 – 1.3)	.75	-0.25 (-1.8 – 1.3)	.76
Age (per year)			0.16 (0.02 – 0.30)	.02	0.06 (-0.08 – 0.20)	.39
Sex (effect of male sex)			4.5 (-0.6 – 9.6)	.09	4.4 (-0.28 – 9.1)	.07
Interaction of time and sex			-1.4 (-3.2 – 0.4)	.13	-1.4 (-3.2 – 0.36)	.13
Kidney disease					19.7 (13.3 – 26.1)	<.001
Hypertension					4.5 (0.6 – 8.4)	.03
Diabetes					-4.0 (-9.7 – 1.7)	.17
Peripheral artery disease					-5.1 (-13.9 – 3.7)	.26
Stroke					2.7 (-5.3 – 10.7)	.51

The table shows the associated estimated changes in proCNP concentration in pmol/L (95%CI) when each variable is entered in a linear mixed model.

CI, confidence interval.


1
2
3 **Figure 1. Mortality rates for increased and normal proCNP in all patients and stratified by sex.**
4
5

6 Display of all-cause mortality rates for groups of normal vs. increased proCNP concentrations in plasma. Graphs of 30-
7 day and one-year mortality rate for all patients are shown in section A and B, respectively. Sex-specific 30-day and one-
8 year mortality rates are shown in section C and D, respectively. The numbers of patients at risk in subgroups are given
9 beneath each graph.
10
11
12
13
14
15
16
17
18

19 **Figure 2. Longitudinal concentrations of proCNP in plasma.**
20
21


22 Concentrations are shown as mean (point) and standard error of the mean (error bars). ProCNP concentrations over time
23 for 287 patients with STEMI are shown in section A. In section B, C, and D, these patients are grouped based on sex,
24 hypertension, and kidney disease, respectively.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



286x199mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



281x187mm (300 x 300 DPI)

Supplemental Material

METHODS

COHORT OF PATIENTS WITH STEMI

Information on age, sex, height, body mass index (BMI), smoking status, development of cardiogenic shock, and cardiac arrest coma, time from onset of symptoms to blood sample, time from blood sample to percutaneous coronary intervention balloon angioplasty, number of coronary vessels affected (defined as the number coronary arteries with at least one stenosis of >70% of the lumen diameter (discrete values of zero to three) from the coronary angiography procedure (CAG)), culprit coronary vessel anatomy, Thrombolysis In Myocardial Infarction (TIMI) grade flow, medical history, left ventricular ejection fraction (LVEF), and routine laboratory measurements was used in the data analyses. Blood samples for baseline biochemical measurements were collected from the femoral or radial sheath on admission immediately before CAG. LVEF was determined by 2D echocardiography performed on admission or within 48 hours of admission. From a consecutive subgroup of the cohort, we collected repeated venous plasma samples during the first days after admission from January to March 2016 at Rigshospitalet (RH) for longitudinal assessment of potential changes in proCNP concentrations. Longitudinal plasma samples were collected at least twice within the first day of admission, and once daily in subsequent days of admission.

BIOCHEMICAL ANALYSES

1
2
3 1 Troponin T was measured in patients admitted to RH by Elecsys Troponin T hs assay
4
5 2 (Cobas, by Roche, Basel, Switzerland), whereas troponin I was measured in patients
6
7 3 admitted to Odense Universitetshospital (OUH) using Architect *STAT* High Sensitive
8
9 4 Troponin-I (Abbott, Chicago, Illinois, United States). Both measurements from samples
10
11 5 on admission and measured peak values during admission (the latter as a proxy of
12
13 6 myocardial infarction size), were used in our statistical analyses. Plasma creatinine was
14
15 7 measured using CREP2 assay and high sensitivity C-reactive protein (hs-CRP) using
16
17 8 CRPHS assay (Cobas, by Roche, Basel, Switzerland). ST2 was measured by Presage
18
19 9 ST2 Assay (Critical Diagnostics, Inc., San Diego, California). We included measurement
20
21 10 of soluble thrombomodulin (sTM) and syndecan-1 as markers of endothelial cell and
22
23 11 glyocalyx damage, respectively. Assay procedures of sTM and syndecan-1 have been
24
25 12 described previously.[1] With regards to measurement of hs-CRP, the results were
26
27 13 analyzed as the proportion of patients with a concentration of ≥ 2 mg/L. This cut-off value
28
29 14 has been introduced as a definition of chronic inflammation in cardiac disease.[2]
30
31 15 Moreover, patients with a time from onset of symptoms to blood sample of ≥ 6 hours are
32
33 16 excluded from hs-CRP analyses because an increase in hs-CRP concentration can be
34
35 17 expected due to myocardial damage.[3,4] For measurement of syndecan-1, sTM, and
36
37 18 hs-CRP, only patients admitted at RH were analyzed. All biochemical analytes, apart
38
39 19 from peak troponins and longitudinal proCNP and proANP, were measured in blood
40
41 20 samples collected on admission.
42
43
44
45
46
47
48
49
50
51
52

53 22 **RESULTS**

54
55
56
57
58
59
60

1 PROCNP MEASUREMENT

2 Coefficients of variation of proCNP measurement in plasma were 13.8% for 20 pmol/L
3 and 13.1% for 40 pmol/L.

4 REFERENCE POPULATION AND STEMI COHORT

5 By inspection of histograms of proCNP concentrations, we concluded that there were no
6 outliers among the individuals. Table 1 shows sex- and age-specific 95% reference
7 intervals of proCNP concentrations in the reference population. Plasma concentrations
8 in males were marginally higher compared to those in females ($P = 0.015$). Women ≥ 50
9 years had higher proCNP concentrations compared to women < 50 years ($P = 0.011$),
10 where no difference was observed among men ($P = 0.44$). The distributions of proCNP
11 concentrations in the reference population and the STEMI cohort are shown in
12 Supplemental Figure 1.

14 **Supplemental Table 1. Reference intervals of proCNP in sex- and age-specific**
15 **groups.**


	Men		Women	
Age groups (years)	<50	≥ 50	<50	≥ 50
Number of subjects	157	173	179	179
95% reference interval	10.2 – 52.2	13.9 – 49.6	13.6 – 48.9	13.4 – 49.4
Median	35.2	36.0	32.2	34.6
Range	4.4 – 55.4	11.4 – 52.4	8.2 – 55.4	4.4 – 60.0

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 Reference intervals, median, and range of proCNP concentrations of subgroups are all
- 2 given in pmol/L.

For peer review only

1 **Supplemental Figure 1. Histograms of relative frequencies of plasma proCNP**
 2 **concentrations.**



3
 4 The reference population is represented by blue bars and the STEMI cohort by red
 5 bars. Each bar represents an interval of 5 pmol/L.

6 Values of >85 pmol/L are not shown.

7
 8 **Cardiogenic shock development and cardiac arrest**


9 When median proCNP concentrations were tested in patients with cardiogenic shock
 10 development vs. no cardiogenic shock development and cardiac arrest coma vs. no

1
2
3 1 cardiac arrest coma or cardiogenic shock development, no differences were observed
4
5 2 ($P = 0.41$ and $P = 0.28$ for females, respectively, and $P = 0.97$ and $P = 0.46$ for males,
6
7 3 respectively).

10
11 4
12
13
14 5 **Time from onset of symptoms to blood sample and correlation of biochemical**
15
16 6 **markers**

17
18
19 7 In Supplemental Figure 2, median plasma proCNP concentrations are shown in
20
21 8 subgroups of different time intervals from onset of symptoms to blood sample. A
22
23 9 difference in proCNP was observed across subgroups ($P < 0.001$). However, when
24
25 10 patients with a time interval of >24 hours were excluded, no difference was found ($P =$
26
27 11 0.091). Information on time from baseline blood sampling (performed when the CAG
28
29 12 procedure was initiated) to percutaneous coronary intervention balloon angioplasty
30
31 13 (time of reperfusion) was obtained on 862 patients (227 women, 635 men). Median
32
33 14 (interquartile range) values in minutes were: 5 (4-9) and 5 (3-9) ($P = 0.90$) for women
34
35 15 with normal and increased proCNP respectively, and 6 (4-10) and 5 (4-10) ($P = 0.17$) for
36
37 16 men with normal and increased proCNP respectively. For biochemical markers with
38
39 17 positive associations to proCNP, we performed Spearman's correlation analyses, and
40
41 18 for proCNP vs. creatinine, proANP, syndecan-1, and sTM, Spearman r were 0.26,
42
43 19 0.082, 0.098, and 0.24, respectively ($P < 0.001$ for all).
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Supplemental Figure 2: Box-plots of proCNP concentrations in groups of time**
 2 **from onset of symptoms to admission.**




3
 4 Boxes indicate median and inter-quartile range, and error bars indicate the interval from
 5 2.5 to 97.5 percentile.

6
 7 **Multivariable Cox regression analyses**


8 We examined the effect of proCNP concentrations as a continuous variable on the
 9 hazard ratio (HR) of one-year all-cause death in all patients as well as females and
 10 males separately by cubic spline plots, using median concentrations as a reference
 11 point (shown in Supplemental Figure 3). In females, there was no effect of proCNP
 12 below median concentrations, whereas the estimated HR increased from approximately
 13 median concentrations to the highest measured concentrations. In males, a trend

1 towards a U-shaped relation was observed with increasing estimated hazard ratios for
2 decreases of proCNP below median and for increases of proCNP above median. Based
3 on these observations we focused our Cox regression analyses on the upper range of
4 proCNP, where we observed that increasing proCNP was associated with increasing
5 HR in both females and males.

6
7 **Supplemental Figure 3: Cubic spline and density plots of hazard ratio and**
8 **proCNP concentrations.**




9



24
25
26
27
28
29

1



30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

2

48
49
50
51
52
53

3

54
55
56
57
58
59
60

4


1 Longitudinal plasma measurements

2 In Supplemental Table 2, the number of patients and samples in groups stratified
 3 according to diseases are shown. Longitudinal measurements of proANP are shown in
 4 Supplemental Figure 4, where the initial decrease from first (0 hours) to second (1-12
 5 hours) timepoint is estimated to be ~850 pmol/L (~85%).

7 Supplemental Table 2: Number of patients and plasma samples in longitudinal 8 analyses.

	Number of patients (females/males)	Number of samples (from females/from males)
Overall	287 (64/223)	907 (211/696)
Kidney disease	26 (6/20)	81 (20/61)
Hypertension	131 (32/99)	412 (96/316)
Diabetes	34 (8/26)	107 (20/87)
Stroke	15 (5/10)	46 (16/30)
PAD	12 (2/10)	40 (6/34)

1 **Supplemental Figure 4: Longitudinal concentrations of proANP in plasma.**



2
3 Concentrations are shown as mean (SEM) for patients with longitudinal plasma
4 samples.

5 **DISCUSSION**

6 *Assay Principle*

7 Our proCNP radioimmunoassay is developed in accordance with a processing-
8 independent principle,[5,6] where different fragments of the prohormone of CNP can be
9 accurately quantitated in circulation regardless of post-translational processing of the
10 prohormone. Also, there is no cross-reactivity to the structurally related cardiac
11 natriuretic propeptides.[7]

1
2
3 1
4
56 2 *Reference Intervals*
7
8

9 3 We based our calculated 95% reference intervals on two age groups of < and ≥ 50
10 4 years. The reason for choosing this division is a previous report showing that NT-
11 5 proCNP concentrations in plasma in healthy individuals increase from ~50 years of
12 6 age.[8] We therefore assume that the two age groups represent two different stages of
13 7 adulthood with regard to circulating NT-proCNP concentrations and, hence, that the two
14 8 age-specific intervals (for each sex) constitute a meaningful reference for interpretation
15 9 of measured proCNP concentrations in the STEMI cohort.

10 *Time from onset of symptoms to blood sampling and balloon angioplasty*
11

12 11 In our baseline and multivariable Cox regressions analyses we have included the time
13 12 from onset of symptoms as a variable, where we have data from the 99.5% of the
14 13 included patients. Our results on time from blood sampling to balloon angioplasty (data
15 14 was obtained from 49.1% of the included patients) show no differences in time between
16 15 groups of normal and increased proCNP in both sexes, where the median time duration
17 16 was 5-6 minutes in all groups. Assuming that the total ischemic time of the STEMI
18 17 patients is equal to the time from onset of symptoms to balloon angioplasty (time of
19 18 reperfusion), our analyses support that the time onset of symptoms to blood sampling
20 19 as a variable also reflects the total ischemic time of the patients.

20 *Correlation Analyses of Biochemical Measurements*
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Correlation analyses showed that the association of proCNP with sTM is superior in
2 comparison to both that of syndecan-1 and proANP. A likely explanation may be that
3 both proCNP and sTM are released from endothelial cells, whereas the glycocalyx and
4 the cardiomyocytes are the major sources of syndecan-1 and proANP, respectively. In
5 contrast to the vascular markers, however, no associations with markers of
6 inflammation, hs-CRP, and ST2 were observed. Thus, proCNP concentrations in
7 plasma do not seem to be affected by general inflammation in patients with STEMI.

8 *Longitudinal Analyses*

9 Repeated measurements displayed a statistically significant decrease in proCNP
10 concentrations over time in a univariate analysis. For comparison we have included
11 repeated measurements of proANP, shown in Supplemental Figure 4. The dynamic
12 response of proANP differs markedly from proCNP with a steep decrease from 0 to 1-12
13 hours and a flat curve from 1-12 to >24 hours. These differences highlight the distinct
14 biological roles of CNP vs. ANP.

15 For proCNP, both multivariate linear mixed models (Model 1 and 2) show that the effect
16 of time was reduced in magnitude and was non-significant, indicating that changes over
17 time are better explained by other variables than time per se. Model 1 found an
18 independent effect of age with higher concentrations of proCNP per year, but Model 2
19 found that the effect of age disappeared when kidney disease and other vascular
20 diseases were included. Thus, age per se does not seem to explain an increase in
21 proCNP concentration; more likely, chronic diseases (where prevalence increases with
22 age) appear a confounder of the crude effect of age. Although a statistically insignificant

1
2
3 1 finding, Model 1 indicates an effect of male sex and an interaction of sex and time that
4
5 2 are unchanged after inclusion of chronic diseases in Model 2. Consistent with the effect
6
7 3 of male sex are previously reported results[8] and the results of the reference population
8
9 4 of the present study, where males have slightly higher concentrations of proCNP-
10
11 5 derived peptides in the circulation. The possible interaction of sex and time, where
12
13 6 males display a relative decrease over time compared with females, has not previously
14
15 7 been reported. However, our longitudinal analyses lack the statistical power to
16
17 8 sufficiently conclude on a potential interaction of sex and time on proCNP
18
19 9 concentrations. In model 2, we find that kidney disease and hypertension are
20
21 10 independently associated with higher proCNP concentrations, consistent with baseline
22
23 11 associations.

24
25
26
27
28
29 12 Of the (cardio)vascular diseases with a crude positive association to increased proCNP
30
31 13 in baseline results, only hypertension is statistically independent in the multivariate
32
33 14 repeated measurement analysis. Unexpectedly, the independent effects of diabetes
34
35 15 mellitus and peripheral artery disease seem to be oppositely directed, where the
36
37 16 diseases are independently associated with lower proCNP concentrations. However,
38
39 17 these results were statistically insignificant, and further studies with more statistical
40
41 18 power are needed to determine if such negative independent associations exist.
42
43
44
45

46 19
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **References**

- 2 1 Frydland M, Ostrowski SR, Møller JE, *et al*. Plasma concentration of biomarkers
3 reflecting endothelial cell- and glycocalyx damage are increased in patients with
4 suspected st-elevation myocardial infarction complicated by cardiogenic shock. *Shock*
5 2018;**50**:538–44. doi:10.1097/SHK.0000000000001123
- 6 2 Libby P, Ridker PM, Hansson GK. Inflammation in Atherosclerosis. From
7 Pathophysiology to Practice. *J Am Coll Cardiol* 2009;**54**:2129–38.
8 doi:10.1016/j.jacc.2009.09.009
- 9 3 Ramasamy I. Biochemical markers in acute coronary syndrome. *Clin Chim Acta*
10 2011;**412**:1279–96. doi:10.1016/j.cca.2011.04.003
- 11 4 Cristell N, Cianflone D, Durante A, *et al*. High-sensitivity C-reactive protein is within
12 normal levels at the very onset of first ST-segment elevation acute myocardial infarction
13 in 41% of cases: A multiethnic case-control study. *J Am Coll Cardiol* 2011;**58**:2654–61.
14 doi:10.1016/j.jacc.2011.08.055
- 15 5 Lippert SK, Rehfeld JF, Goetze JP. Processing-independent analysis for pro-C-type
16 natriuretic peptide. *J Immunol Methods* 2010;**362**:32–7. doi:10.1016/j.jim.2010.08.003
- 17 6 Rehfeld J, Goetze J. The Posttranslational Phase of Gene Expression: New Possibilities
18 in Molecular Diagnosis. *Curr Mol Med* 2005;**3**:25–38. doi:10.2174/1566524033361717
- 19 7 Nielsen SJ, Rehfeld JF, Goetze JP. Mismeasure of C-type natriuretic peptide [7]. *Clin.*
20 *Chem.* 2008;**54**:225–7. doi:10.1373/clinchem.2007.096172
- 21 8 Prickett TCR, Olney RC, Cameron VA, *et al*. Impact of age, phenotype and cardio-renal
22 function on plasma C-type and B-type natriuretic peptide forms in an adult population.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Clin Endocrinol (Oxf)* 2013;**78**:783–9. doi:10.1111/cen.12035

2

For peer review only

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1 3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	7-8
Objectives	3	State specific objectives, including any prespecified hypotheses	7-8
Methods			
Study design	4	Present key elements of study design early in the paper	8-12
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8-11
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	8-10
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-11 + suppl.
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10 + suppl.
Bias	9	Describe any efforts to address potential sources of bias	-
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10-11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	10-12 + suppl.
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	12-15 + table 1-2 + figure 1 +suppl
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12-15 + table 1-2 + figure 1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		(b) Indicate number of participants with missing data for each variable of interest	+suppl
		(c) Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Report numbers of outcome events or summary measures over time	table 2 + figure 1

For peer review only

1 2 3 4 5 6 7 8 9 10 11	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	12-15 + table 1-2 + figure 1 +suppl
12 13 14 15 16 17 18	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12-15 + table 1-2 + figure 1-2 +suppl
19	Discussion			
20	Key results	18	Summarise key results with reference to study objectives	15-19
21 22 23	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18
24 25	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15-19
26 27	Generalisability	21	Discuss the generalisability (external validity) of the study results	15-18
28	Other information			
29 30 31 32	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Sex-specific Mortality Prediction by Pro-C-type Natriuretic Peptide Measurement in a Prospective Cohort of Patients with ST-elevation Myocardial Infarction

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048312.R1
Article Type:	Original research
Date Submitted by the Author:	22-Apr-2021
Complete List of Authors:	Mark, Peter; Copenhagen University Hospital, Clinical Biochemistry Frydland, Martin; Copenhagen University Hospital, Cardiology Helgestad, Ole ; Odense Universitetshospital, Cardiology Holmvang, Lene; Copenhagen University Hospital, Rigshospitalet, Cardiology Møller, Jacob; Odense Universitetshospital, Department of cardiology Johansson, Pär I; Copenhagen University Hospital, Clinical Immunology Ostrowski, Sisse; Copenhagen University Hospital, Clinical Immunology Prickett, Timothy; Otago University Canterbury Medical Library, Cardiology Hassager, Christian; The University Hospital of Copenhagen, Cardiology Goetze, Jens Peter; Copenhagen University Hospital, Clinical Biochemistry
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Intensive care
Keywords:	Myocardial infarction < CARDIOLOGY, Cardiology < INTERNAL MEDICINE, Adult cardiology < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **Sex-specific Mortality Prediction by Pro-C-type Natriuretic Peptide Measurement**
4
5 2 **in a Prospective Cohort of Patients with ST-elevation Myocardial Infarction**
6
7

8 3 Peter D. Mark, MD¹; Martin Frydland, MD²; Ole K. L. Helgestad, MD³; Lene Holmvang,
9 MD, DMSc³; Jacob E. Møller, MD, DMSc³; Pär I. Johansson, MD, DMSc⁴; Sisse R.
10 Ostrowski, MD, DMSc⁴; Timothy C. R. Prickett, PhD⁵; Christian Hassager, MD, DMSc²;
11 Jens P. Goetze, MD, DMSc^{1,6}
12

13 7 ¹Department of Clinical Biochemistry, Copenhagen University Hospital, Rigshospitalet,
14 8 Copenhagen, Denmark

15 9 ²Department of Cardiology, Copenhagen University Hospital, Rigshospitalet,
16 10 Copenhagen, Denmark

17 11 ³Department of Cardiology, Odense University Hospital, Odense, Denmark

18 12 ⁴Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet,
19 13 Copenhagen, Denmark

20 14 ⁵Department of Medicine, University of Otago, Christchurch, New Zealand

21 15 ⁶Department of Biomedical Sciences, Faculty of Health Sciences, Copenhagen
22 16 University, Copenhagen, Denmark

23 17
24 18 **Word count (Introduction to conclusion):** 3319

25 19 **Correspondence:** Jens P. Goetze, MD, DMSc

26 20 Professor, Chief Physician

27 21 Department of Clinical Biochemistry KB3013

28 22 9 Blegdamsvej, DK-2100 Copenhagen, Denmark

29 23 Phone: +45-3545-2202, Fax: +45-3545-2880, E-mail: JPG@dadlnet.dk

30 24 **Keywords:** Natriuretic peptides, C-type natriuretic peptide, CNP, ANP, Reference
31 25 intervals, Myocardial infarction.

1
2
3 1 **List of abbreviations:** CNP, C-type natriuretic peptide; ACS, acute coronary syndrome;
4
5 2 NT-proCNP, amino-terminal proCNP; STEMI, ST-elevation myocardial infarction;
6
7 3 proCNP (see Nomenclature); NOBIDA, Nordic Reference Interval Project Biobank and
8
9 4 Database; RH, Copenhagen University Hospital, Rigshospitalet; OUH, Odense
10
11 5 University Hospital; CAG, coronary angiography; ECG, electrocardiogram; BMI, body
12
13 6 mass index; LVEF, left ventricular ejection fraction; hs-CRP, high sensitivity c-reactive
14
15 7 protein; sTM, soluble thrombomodulin.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Abstract**

2 **Objective:** To determine the predictive value of pro-C-type natriuretic peptide (proCNP)
3 measurement in plasma sampled on admission from patients presenting with ST-
4 elevation myocardial infarction (STEMI).

5 **Design:** Prospective cohort study.

6 **Setting:** Two University Hospitals in Denmark.

7 **Participants:** 1760 consecutive patients (470 females and 1290 males) with confirmed
8 STEMI.

9 **Main Outcomes and Measures:** The main outcome was all-cause mortality at one year
10 after presentation and the primary measure was proCNP concentration in plasma at
11 admission in all patients and longitudinal measurements in a consecutive subgroup of
12 287 patients. A reference population (n = 688) defined cut-off values of increased
13 proCNP concentrations.

14 **Results:** In all patients, an increased proCNP concentration was associated with a
15 higher all-cause mortality after one year (HR: 1.6 (1.1-2.4), $P_{\text{logrank}} = .009$) including an
16 interaction of sex ($P = .03$). In separate sex-stratified analyses, female patients showed
17 increased all-cause mortality (HR_{one year}: 2.6 (1.5-4.6), $P_{\text{logrank}} < .001$), whereas no
18 differences were found in male patients (HR_{one year}: 1.1 (.7-1.9), $P_{\text{logrank}} = .66$). After
19 adjusting for potential risk factors, we found increased proCNP concentrations \geq the
20 median value to be independently associated with increased risk of mortality in female
21 patients within one year (HR per 1 pmol/L increase: 1.04 (1.01-1.06), $P = .007$).

1
2
3 1 Moreover, we found indications of sex differences in proCNP concentrations over time
4
5 2 (higher proCNP in males (4.4 (-.28 – 9.1) pmol/L, P= .07) and interaction of sex and
6
7 3 time (P= .13)), and that hypertension was independently associated with higher proCNP
8
9 4 (4.5 (.6-8.4) pmol/L, P= .03).

10
11
12
13 5 **Conclusions:** In female but not male patients presenting with STEMI, high
14
15 6 concentrations of proCNP (\geq median) at admission independently indicate a higher risk
16
17 7 of all-cause mortality. The findings are remarkably specific for female patients,
18
19 8 suggesting a different vascular phenotype beyond traditional measures of coronary
20
21 9 artery flow compared to male patients.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Strengths and limitations of this study

- 2 • The is the first study to investigate the prognostic potential of measurement of
3 peptides derived from pro-C-type natriuretic peptide (proCNP) by using
4 predefined sex- and age-specific cut-off values based on a reference population.
- 5 • As a novel approach, a large cohort of patients are examined during the acute
6 phase of ST-elevation myocardial infarction with plasma sampling at admission
7 and all-cause mortality within one year as main outcome.
- 8 • To clarify the temporal pattern of proCNP concentrations, longitudinal
9 measurements during admission in a subgroup of the cohort are used to further
10 examine sex differences and baseline associations.
- 11 • The sex-specific analyses are exploratory and the present report should be
12 considered a hypothesis-generating study.
- 13 • As all-cause mortality within one year is the only available outcome measure,
14 other clinical end-points and long-term follow-up is not investigated.

1 Introduction

2 Despite the structural resemblance to the cardiac hormones, atrial and B-type natriuretic
3 peptides (ANP and BNP), C-type natriuretic peptide (CNP) differs functionally from the
4 two other family members.[1] CNP is a paracrine/autocrine peptide expressed in many
5 tissues,[2] including endothelial cells.[3] Experimental studies have shown that
6 endothelial-derived CNP is locally involved in regulation of vascular tone[4,5] and
7 angiogenesis.[6] Also, a recent preclinical investigation has suggested that CNP plays a
8 key protective role in cardiac pathophysiology.[7]

9 Clinical reports on the general population as well as patients with heart disease have
10 examined circulating proCNP-derived peptides as prognostic markers.[8–10] In patients
11 presenting with acute coronary syndrome (ACS), high concentrations of amino-terminal
12 proCNP (NT-proCNP) in plasma measured 4-6 weeks after the event were reported to
13 be the only natriuretic peptide to independently predict cardiac readmission and death in
14 the patients with unstable angina.[8] Taken together, experimental and epidemiological
15 data suggest CNP to be an important regulator of cardiovascular function and that
16 increased concentrations of proCNP-derived peptides in plasma of patients reflect an
17 unfavorable cardiovascular condition as a compensatory response to cardiovascular
18 disease. However, no previous large study has explored the prognostic value of
19 measurement of proCNP-derived peptides in the acute phase of an ST-elevation
20 myocardial infarction (STEMI).[11]

21 In this study, we measured concentrations of the precursor of C-type natriuretic
22 peptides (proCNP) in plasma from a large cohort of patients presenting with STEMI,

1 where baseline blood samples were collected when patients were admitted (before
2 coronary intervention). Previously, we have reported on this method for accurate
3 quantification of “total” proCNP in plasma by a processing-independent
4 radioimmunoassay.[12] We determined proCNP concentration as a predictor of all-
5 cause mortality within one year and examined for potential sex-differences. Moreover,
6 we investigated a large consecutive subgroup of patients with STEMI from the cohort
7 with longitudinal plasma samples collected during the hospital admission to examine
8 proCNP concentrations over time and further analyze baseline associations between
9 proCNP concentrations and vascular diseases. Finally, we included a large sample of
10 healthy individuals in order to, independently of the patient cohort, establish age- and
11 sex-specific reference intervals for proCNP concentrations in plasma.

12 *Nomenclature*

13 ProCNP: In the present article, proCNP refers to a specific amino-acid sequence
14 (human proCNP 11-27) within the prohormone sequence of CNP; the epitope of the
15 antiserum of our radioimmunoassay. In this processing-independent methodology, we
16 utilize this fragment after enzymatic cleavage in vitro as a proxy measure of all proforms
17 released to plasma irrespective of prohormone post-translational processing.

18 ProCNP-derived peptides: Collective term for any fragment of the prohormone of CNP.

19 **Methods**

20 REFERENCE POPULATION

1
2
3 1 For establishment of reference intervals, we used plasma samples from the Nordic
4
5 2 Reference Interval Project Biobank and Database (NOBIDA), originally consisting of
6
7 3 3002 subjects.[13] A subgroup of 853 subjects from this population was randomly
8
9 4 selected with the aim to represent sex, age, and country of origin equally, as previously
10
11 5 described.[14]
12
13
14

15 6 COHORT OF PATIENTS WITH STEMI

16
17
18 7 Patients with suspected STEMI were consecutively included from two Danish hospitals
19
20 8 over a period of one year (2015/2016) (Copenhagen University Hospital, Rigshospitalet
21
22 9 (RH), and Odense University Hospital (OUH)). The procedure of inclusion has been
23
24 10 described previously.[15] From this cohort of patients with suspected STEMI and triaged
25
26 11 for acute coronary angiography (CAG) (based on assessment of symptoms and the
27
28 12 individual electrocardiogram (ECG)), we only included patients with confirmed
29
30 13 STEMI.[16] All patients underwent CAG and baseline blood samples were obtained
31
32 14 immediately before CAG was performed (See further details on data collection including
33
34 15 blood sampling in the Supplemental Material).
35
36
37
38
39

40 16 PATIENT AND PUBLIC INVOLVEMENT

41
42
43 17 Patients and/or the public were not involved in the design, or conduct, or reporting, or
44
45 18 dissemination plans of this research.
46
47

48 19 ETHICS

49
50
51
52 20 Patients gave written informed consent. When patients were not able to provide this
53
54 21 (e.g. comatose cardiac arrest patients), consent was obtained by the patients' next of
55
56
57
58
59
60

1 kin and general practitioners in accordance with national legislation. The study was
2 approved by the Local Committee on Health Research Ethics (Copenhagen) (Ref. H-2-
3 2014-110).

4 BIOCHEMICAL ANALYSES

5 Plasma proANP and proCNP concentrations were quantified by the previously reported
6 processing-independent assay technology and procedures.[12,17,18] Information of
7 other biochemical analyses can be found in the Supplemental Material.

8 ALL-CAUSE MORTALITY

9 The Danish Civil Registration System was used for all-cause mortality assessment. All
10 Danish citizens are recorded with a unique 10-digit civil registration number, and deaths
11 are registered within 2 weeks. Initial follow-up began on the date of admission and
12 continued until date of death, or October 30th, 2017.

13 MAIN OUTCOMES

14 The primary outcome was one-year all-cause mortality. We tested 30-day all-cause
15 mortality as a secondary outcome. We focused on sex-specific estimates as we found a
16 statistical interaction of sex and proCNP concentrations on mortality.

17 STUDY DESIGN

18 The study design is summarized in Figure 1.

19 STATISTICS

20 *Reference Population*

1
2
3 1 We divided the reference population into groups based on sex and age (<50 and ≥50
4
5 2 years) and used the RefVal software[19] to calculate 95% reference intervals based on
6
7 3 a non-parametric bootstrapping method. See Supplemental Table 1 for results on
8
9 4 reference intervals.

5 *STEMI Cohort*

6 Based on their respective sex- and age-specific reference interval from the reference
7
8 7 population, all STEMI patients were stratified according to a) increased proCNP
9
10 8 concentration (higher than the 95% reference interval), b) normal proCNP concentration
11
12 9 (within the 95% reference interval), and c) decreased proCNP concentration (lower than
13
14 10 the 95% reference interval). Dichotomous variables are presented as numbers (n) and
15
16 11 percentages (%). Continuous variables are presented as medians with 25th–75th
17
18 12 percentiles. Comparisons between groups were done using independent non-
19
20 13 parametric t-tests and Fisher's exact two-sided test. Spearman's correlation analyses
21
22 14 were used to assess the relationships between proCNP and other biochemical analytes.
23
24 15 Differences in median proCNP concentrations at different time intervals from onset of
25
26 16 symptoms to blood sample were assessed by Kruskal-Wallis tests (this time parameter
27
28 17 also reflects total ischemic time; see Supplemental Material). All-cause mortality after 30
29
30 18 days and one year was assessed in patients stratified into normal or increased proCNP
31
32 19 concentrations and depicted by Kaplan-Meier plots and then compared with the log-rank
33
34 20 test and estimates of hazard ratio including 95% confidence intervals. We performed a
35
36 21 statistic test of interaction between sex and groups of proCNP. To test the relation of
37
38 22 mortality and proCNP concentrations on a continuous scale, we performed cubic spline
39
40 23 plots with the density distribution and the logarithm of hazard ratios. We focused our

1 further mortality analyses on proCNP concentrations \geq median, where we observed an
2 effect of increasing proCNP concentrations on mortality (patients were divided into
3 groups of \geq vs. $<$ median proCNP according to sex- and age-specific median proCNP
4 concentrations of the reference population shown in the Supplemental Material). Thus,
5 for patients with a baseline proCNP concentration \geq median, multivariable Cox
6 proportional hazard models including proCNP, age, plasma creatinine, plasma proANP,
7 time from onset of symptoms to blood sample, number of coronary vessels affected and
8 tertiles of peak plasma troponin concentrations were constructed for mortality
9 assessment. Both plasma proANP and creatinine were logarithmically transformed,
10 where peak troponin T and troponin I were combined in one variable of tertiles
11 (represented by values of one to three) as a proxy myocardial infarction size, before
12 being entered into the model. For longitudinal analyses, we constructed four time
13 points/intervals for statistical analyses (1: samples from admission; 2: 1 to 12 hours
14 after admission; 3: >12 to 24 hours after admission; 4: >24 hours after admission). We
15 used linear mixed models of unstructured co-variances to examine changes in
16 concentrations and associations with co-variables over time. Statistical analyses were
17 performed using RefVal software²⁰ for calculation of reference intervals, statistical
18 software R version 3.6.1 (R Core Team, Vienna, Austria[20]) for linear mixed models
19 (nlme package), and IBM SPSS Statistics 22 (SPSS Inc., Chicago, Illinois, United
20 States) for other analyses. A *P*-value $<.05$ was considered statistically significant.

21 **Results**

22 *Reference population*

1 We measured proCNP concentrations in available plasma from 688 subjects (358
2 females; 330 males). From these measurements, 95% reference intervals for females
3 vs. males and < vs. ≥ 50 years were calculated (see results in the Supplemental Table
4 1).

5 *STEMI Cohort*

6 From the cohort of 2247 patients with suspected STEMI, 1760 patients (460
7 females and 1290 males) with verified STEMI and available plasma were included in
8 our study (see a flowchart of the inclusion in Supplemental Figure 1 and the relative
9 frequencies of measured proCNP concentrations in Supplemental Figure 2). When
10 compared to the sex- and age-specific reference intervals, a total of 283 (16.1%) of the
11 patients had an increased proCNP concentration; no difference in sex-specific
12 proportions was observed ($P = .42$).

13 *Baseline analyses*

14 Table 1 shows the baseline characteristics and follow-up in patient groups defined by
15 normal or increased proCNP concentrations. Five patients (one male and four females)
16 displayed decreased proCNP concentrations and were not included in Table 1. Missing
17 individual information on each variable in each group was between .1% and 4.4%,
18 except for age, sex, mortality, cardiogenic shock, cardiac arrest coma, time from onset
19 of symptoms to blood sample, and Thrombolysis in Myocardial Infarction (TIMI) grade
20 flow, where information from all patients was available (see Supplemental Table 2 for
21 results on culprit vessel, number of coronary vessels affected and TIMI grade flow).
22 Female patients with increased proCNP concentrations at admission had a higher

1 prevalence of hypertension ($P = .003$), diabetes mellitus ($P = .022$), peripheral artery
2 disease ($P = .002$), and chronic kidney disease (CKD) ($P < .001$), whereas male
3 patients had higher prevalence of hypertension ($P = .004$), stroke ($P = .012$), and CKD
4 ($P < .001$). Increased proCNP was associated with higher concentrations of proANP (P
5 = .019) and soluble thrombomodulin (sTM) ($P = .001$) in female patients and with higher
6 concentrations of creatinine ($P < .001$), syndecan-1 ($P = .019$), and sTM ($P = .003$) in
7 male patients. Lastly, we found a higher one-year mortality rate ($P = .001$) and
8 prevalence of cardiogenic shock development ($P = .013$) in female patients with
9 increased proCNP concentrations, whereas no differences were found in male patients.
10 For biochemical markers with positive associations to proCNP, we performed
11 Spearman's correlation analyses (see the Supplemental Material for results). For results
12 on median proCNP concentrations in groups of time from onset of symptoms to blood
13 sample, see Supplemental Material including Supplemental Figure 3).

14 *Mortality analyses*

15 Thirty-days and one-year all-cause mortality plots of normal and increased proCNP
16 concentrations of all patients and stratified by sex are depicted in Figure 2. Different
17 mortality rates were found for all patients at both time points ($HR_{30\text{ days}} = 1.6$ (1.0-2.6),
18 $P_{logrank} = .03$ and $HR_{one-year} = 1.6$ (1.1-2.4), $P_{logrank} = .009$). However, we found an
19 interaction of sex and groups of proCNP ($P = .03$). In sex-specific estimates, only
20 female patients showed different mortality rates (females_{30 days}: $HR = 2.8$ (1.4-5.6),
21 $P_{logrank} = .002$, females_{one-year}: $HR = 2.6$ (1.5-4.6), $P_{logrank} < .001$, males_{30 days}: $HR = 1.1$
22 (0.6-2.1), $P_{logrank} = .87$, and males_{one-year}: $HR = 1.1$ (.7-1.9), $P_{logrank} = .66$). In cubic spline
23 plots, we observed an effect of increasing proCNP as a continuous variable on mortality

1 from median concentrations in both sexes. We therefore focused on this upper range of
2 proCNP concentrations in Cox regression analyses (see Supplemental Figure 4). In a
3 univariate Cox proportional hazard model, we found an elevated hazard ratio (HR) of
4 all-cause mortality with increases of plasma proCNP for both sexes (results shown in
5 Table 2). When including age and plasma creatinine in a multivariable model (Model 1),
6 proCNP was independently associated with mortality in female but not in male patients
7 (see Table 2): HR (95% CI) for female patients was 1.04 (1.01-1.07) ($P = .008$) for 30-
8 day and 1.03 (1.01-1.06) ($P = .010$) for one-year mortality, whereas HR was 1.00 for
9 both all patients and male patients at both time points (see Table 2). In a model where
10 proANP, tertiles of peak troponins, number of vessels affected, and time from onset of
11 symptoms to admission were also added (Model 2), risk estimates of proCNP (per one
12 pmol/L increase) were: HR (95% CI) = 1.04 (1.01-1.07), $P = .016$ for 30-day mortality,
13 and HR (95% CI) = 1.04 (1.01-1.06), $P = .007$ for one-year mortality.

14 *Longitudinal analyses*

15 To examine proCNP concentrations over time during a STEMI and further test the
16 baseline associations of vascular disease and increased proCNP, we used a set of
17 longitudinal plasma samples from a consecutive subgroup of the cohort consisting of
18 287 STEMI patients (64 females and 223 males). Results are shown in Figure 3 and
19 Table 3. An overall decrease in proCNP concentration was estimated to be 3.8 pmol/L
20 (~10%) ($P = .001$) from admission to >24 hours. In a multivariate model including sex,
21 age, and chronic diseases (Model 3), CKD and hypertension were independently
22 associated with higher concentrations of proCNP ($P < .001$ and $P = .03$, respectively),
23 whereas time and age were not independently associated with changes in proCNP.

1
2
3 1 Also, both Model 2 and 3 implied a positive association of proCNP concentration and
4
5 2 male sex, and an interaction of time and sex; however, the statistical uncertainty of
6
7 3 these estimates was substantial ($P = .07$ and $P = .13$, respectively). Figure 3 shows
8
9 4 proCNP concentrations over time in overall and sex-specific graphs including graphs of
10
11 5 CKD and hypertension (see the Supplemental Material including Supplemental Table 3
12
13 6 and Supplemental Figure 5 for further results of longitudinal measurements).
14
15
16
17

18 7 **Discussion**

19
20
21 8 In this study, we report on a marked sex-specific prognostic information profile for
22
23 9 proCNP measurement in patients presenting with a STEMI. A major advantage of our
24
25 10 present approach comes from an independent establishment of a sex-specific proCNP
26
27 11 reference interval prior to patient measurement. This allowed us to perform clinically
28
29 12 meaningful divisions of normal, decreased, or increased proCNP concentrations in
30
31 13 plasma specific to sex, rather than testing differences only within the patient cohort as a
32
33 14 whole (see the Supplemental Material for discussion of age groups).
34
35
36
37

38 15 In this cohort of consecutive patients with a verified STEMI, we show that 16.1%
39
40 16 have increased concentrations of proCNP during the early phase of the myocardial
41
42 17 infarction compared with the sex- and age-specific intervals. Interestingly, besides
43
44 18 higher prevalence of CKD, we found a markedly higher prevalence of cardiovascular
45
46 19 disease including hypertension in both sexes; diabetes mellitus and peripheral artery
47
48 20 disease for female patients; and stroke for males among patients with increased
49
50 21 proCNP. Our longitudinal analyses of a subgroup of the STEMI patients corroborates
51
52 22 that the association to both CKD and hypertension is consistent even over time and is
53
54
55
56
57
58
59
60

1 independent of sex, age, and other cardiovascular diseases. A putative explanation for
2 the linkage of hypertension and increased proCNP concentrations is the upregulation of
3 CNP expression by vascular shear stress.[21,22] The positive association of proCNP
4 and a vascular marker, sTM, for both sexes also support the relation of circulating
5 proCNP with vascular stress. In contrast, the baseline associations of increased
6 proCNP concentrations and diabetes, peripheral artery disease and stroke, respectively,
7 are not statistically independent in longitudinal analyses. However, given the sex-
8 specific pattern in the baseline findings and the limited number of patients with the
9 respective diseases in longitudinal analyses, the results may be too preliminary to
10 sufficiently conclude on the potential associations to diabetes, peripheral artery disease,
11 and stroke. Also, the statistical uncertainty of the suggested effect of sex and interaction
12 of sex and time in longitudinal analyses calls for a cautious interpretation (see the
13 Supplemental Material for further discussion of longitudinal analyses).

14 The risks of death within 30 days and one year were higher for female patients
15 with increased proCNP concentrations – but not for male patients. This marked sex-
16 specific association was confirmed when the mortality rate was analyzed by increases
17 of proCNP \geq median, where proCNP proved to be an independent predictor in a model
18 (Model 1 in Table 2) including two additional variables, age and plasma creatinine,
19 which have previously established associations with NT-proCNP in plasma.[23] To
20 further test the prognostic potential of proCNP, we added plasma proANP, tertiles of
21 peak troponins, number of vessels affected, and time from onset of symptoms to
22 admission into a multivariable model (Model 2). In this model, increases of proCNP
23 were still independently associated with the risk of death, and the estimates were of

1 similar size at both time points. Recent data on patients with STEMI found no
2 independent prognostic value on mortality rate for NT-proCNP concentrations.[8]
3 However, that report differed from ours in several aspects including radioimmunoassay
4 principle and duration of follow-up, and, importantly, plasma was sampled 4-6 weeks
5 after admission in contrast to our real-time STEMI investigation. These differences
6 make a direct comparison difficult.

7 Our results firmly suggest a sex-specific association with survival, where
8 increased proCNP concentrations indicate a poorer prognosis in female patients.
9 Previously, studies have shown that CNP acts as a more potent vasodilator in female
10 porcine arteries[24] and that the female sex hormone estradiol upregulates the
11 expression of CNP in vascular endothelial cells.[25] Furthermore, recent preclinical
12 reports have convincingly pointed to a pivotal role of CNP and its receptors in the
13 regulation of the microcirculation[5] and in cardiac homeostasis.[26] Taken together,
14 these previous findings suggest that the CNP system is a critical modulator of vascular
15 integrity and function including a more pronounced vasodilatory capacity in females that
16 may be provided by female sex hormones. Clinical evidence shows that females display
17 a sharp rise in the incidence of cardiovascular disease after menopause and that
18 changes in sex hormones by complex mechanisms play a key role in the loss of
19 vasoprotection.[27,28] Notably, postmenopausal females are at higher risk of coronary
20 microvascular dysfunction and HFpEF compared with their male counterparts,[29] and
21 high concentrations of NT-proCNP have previously been independently linked to an
22 adverse outcome in patients with HFpEF.[9] In this perspective, we speculate that our
23 observed sex-specific effect of increased proCNP concentrations in plasma of patients

1
2
3 1 with STEMI partly reflects ongoing vascular dysfunction in females in particular and,
4
5 2 hence, represents an independent signal of poor cardiovascular prognosis. However,
6
7 3 there is a need for translational research to elucidate this association between
8
9 4 increased proCNP in females with vascular complications and increased mortality rate.
10
11 5 Furthermore, there is a paucity of reports examining a potential racial impact on
12
13 6 concentrations of circulating proCNP-derived peptides. As the majority of Danish and
14
15 7 Scandinavian population are Caucasian, it remains to be investigated whether our
16
17 8 results can be extrapolated to other populations.
18
19
20
21

22 9 *Limitations*

23
24
25 10 While the number of patients with STEMI in the cohort is high, the follow-up period is
26
27 11 relatively short. We examined only all-cause mortality as outcome in our follow-up
28
29 12 multivariable Cox regression analyses, and other clinical endpoints, e.g., cardiac
30
31 13 readmission, were not tested. Hence, the number of events limits the number of
32
33 14 possible covariates in the multivariable Cox regression analyses (Model 3), and sex-
34
35 15 specific estimates of 30-day mortality in this model should be interpreted cautiously.
36
37 16 Moreover, this study focused on increased proCNP and the upper range of proCNP
38
39 17 concentrations in plasma, whereas associations of decreased proCNP concentrations
40
41 18 were not investigated. With regard to measurement of troponins in plasma, two different
42
43 19 analytes (TnT and TnI) were measured at the two hospitals of inclusion. Thus, a
44
45 20 combined variable of tertiles of peak troponins (discrete values of one to three) was
46
47 21 included in the multivariable models with less quantitative information than the
48
49 22 measured concentrations. Baseline biochemical analyses were performed on arterial
50
51 23 plasma, whereas venous plasma was used from the reference population and in
52
53
54
55
56
57
58
59
60

1
2
3 1 repeated measurements. A previous report has shown slightly lower plasma
4
5 2 concentrations of NT-proCNP in arterial compared with venous plasma.[30] Thus, in
6
7 3 theory, our approach will underestimate the proportion of STEMI patients with increased
8
9 4 proCNP concentration and the initial longitudinal decrease in proCNP concentration
10
11 5 from baseline to the second time point (0 to 1-12 hours).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Conclusions**

2 We show here that increased proCNP concentrations in plasma from patients
3 presenting with STEMI are associated with a higher all-cause mortality rate within one
4 year among female patients with STEMI, whereas male patients display no such
5 pattern. Moreover, we report that an increase of proCNP in the upper range of plasma
6 concentrations (\geq median) in female patients is an independent prognostic marker of
7 mortality at both 30 days and one year. The findings are remarkably specific for female
8 patients, suggesting a different vascular phenotype beyond traditional measures of
9 coronary artery flow compared to male patients.

1 **Acknowledgements**

2 We are grateful to laboratory technicians Marie Ziebell Severinsen and Anne Truesen
3 Asanovski for their expertise regarding proANP and proCNP measurement in plasma.

4 **Contributors**

5 Designed the study: PDM, MF, CH, JPG. Designed and conducted the STEMI cohort
6 study: MF, OKLH, LH, JEM, CH. Undertook biochemical measurements: PDM, SRO,
7 PIJ, JPG. Performed the data analysis: PDM, MF, TCRP. Wrote the manuscript draft:
8 PDM. Revised the paper based on intellectual contribution: PDM, MF, OKLH, LH, JEM,
9 PIJ, SRO, TCRP, CH, JPG.

10 **Funding**

11 Research grants from Rigshospitalet.

12 **Competing interests**

13 None to report.

14 **Patient and public involvement**

15 Patients and/or the public were not involved in the design, or conduct, or reporting, or
16 dissemination plans of this research.

17 **Ethics approval**

18 The study was approved by the local ethics committee (Copenhagen) (Ref. H-2-2014-
19 110).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Data availability statement**

2 Data are available upon reasonable request (email: JPG@dadlnet.dk).

For peer review only

1 1 **References**

- 2 1 Goetze JP, Bruneau BG, Ramos HR, *et al.* Cardiac natriuretic peptides. *Nat. Rev.*
3 2 *Cardiol.* 2020;**17**:698–717. doi:10.1038/s41569-020-0381-0
- 4 2 Sellitti DF, Koles N, Mendona MC. Regulation of C-type natriuretic peptide
5 3 expression. *Peptides.* 2011;**32**:1964–71. doi:10.1016/j.peptides.2011.07.013
- 6 3 Stingo AJ, Clavell AL, Heublein DM, *et al.* Presence of C-type natriuretic peptide
7 4 in cultured human endothelial cells and plasma. *Am J Physiol - Hear Circ Physiol*
8 5 1992;**263**:H1318-21. doi:10.1152/ajpheart.1992.263.4.h1318
- 9 4 Nakao K, Kuwahara K, Nishikimi T, *et al.* Endothelium-Derived C-Type Natriuretic
10 6 Peptide Contributes to Blood Pressure Regulation by Maintaining Endothelial
11 7 Integrity. *Hypertension* 2017;**69**:286–96.
12 8 doi:10.1161/HYPERTENSIONAHA.116.08219
- 13 5 Špiranec K, Chen W, Werner F, *et al.* Endothelial C-type natriuretic peptide acts
14 9 on pericytes to regulate microcirculatory flow and blood pressure. *Circulation*
15 10 2018;**138**:494–508. doi:10.1161/CIRCULATIONAHA.117.033383
- 16 6 Bubb KJ, Aubdool AA, Moyes AJ, *et al.* Endothelial C-Type Natriuretic Peptide Is
17 11 a Critical Regulator of Angiogenesis and Vascular Remodeling. *Circulation*
18 12 2019;**139**:1612–28. doi:10.1161/CIRCULATIONAHA.118.036344
- 19 7 Parmar KM, Larman HB, Dai G, *et al.* Integration of flow-dependent endothelial
20 13 phenotypes by Kruppel-like factor 2. *J Clin Invest* 2006;**116**:49–58.
21 14 doi:10.1172/JCI24787

- 1
2
3 1 8 Prickett TCR, Doughty RN, Troughton RW, *et al.* C-type natriuretic peptides in
4 coronary disease. *Clin Chem* 2017;**63**:316–24.
5
6 2
7
8 3 doi:10.1373/clinchem.2016.257816
9
10
11 4 9 Lok DJ, Klip IJT, Voors AA, *et al.* Prognostic value of N-terminal pro C-type
12 natriuretic peptide in heart failure patients with preserved and reduced ejection
13 fraction. *Eur J Heart Fail* 2014;**16**:958–66. doi:10.1002/ejhf.140
14
15
16 6
17
18 7 10 Sangaralingham SJ, McKie PM, Ichiki T, *et al.* Circulating C-Type Natriuretic
19 Peptide and Its Relationship to Cardiovascular Disease in the General Population.
20
21
22 8
23 9 *Hypertension* 2015;**65**:1187–94. doi:10.1161/HYPERTENSIONAHA.115.05366
24
25
26 10 11 Pemberton CJ, Siriwardena M, Kleffmann T, *et al.* C-type natriuretic peptide
27 (CNP) signal peptide fragments are present in the human circulation. *Biochem*
28
29 11
30
31 12 *Biophys Res Commun* 2014;**449**:301–6. doi:10.1016/j.bbrc.2014.05.020
32
33
34 13 12 Lippert SK, Rehfeld JF, Goetze JP. Processing-independent analysis for pro-C-
35 type natriuretic peptide. *J Immunol Methods* 2010;**362**:32–7.
36
37 14
38
39 15 doi:10.1016/j.jim.2010.08.003
40
41
42 16 13 Felding P, Rustad P, Mårtensson A, *et al.* Reference individuals, blood collection,
43 treatment of samples and descriptive data from the questionnaire in the Nordic
44 Reference Interval Project 2000. *Scand J Clin Lab Invest* 2004;**64**:327–42.
45
46 18
47
48 19 doi:10.1080/00365510410006630
49
50
51 20 14 Mark PD, Hunter I, Terzic D, *et al.* Processing-independent proANP measurement
52 for low concentrations in plasma: Reference intervals and effect of body mass
53
54
55
56
57
58
59
60

- 1
2
3 1 index and plasma glucose. *Clin Chem Lab Med* 2017;**56**:132–7.
4
5 2 doi:10.1515/cclm-2017-0309
6
7
8 3 15 Obling L, Frydland M, Hansen R, *et al*. Risk factors of late cardiogenic shock and
9 mortality in ST-segment elevation myocardial infarction patients. *Eur Hear journal*
10
11 4 *Acute Cardiovasc care* 2018;**7**:7–15. doi:10.1177/2048872617706503
12
13 5
14
15
16 6 16 Thygesen K, Alpert JS, Jaffe AS, *et al*. Third universal definition of myocardial
17 infarction. *Circulation* 2012;**126**:2020–35. doi:10.1161/CIR.0b013e31826e1058
18
19 7
20
21
22 8 17 Rehfeld J, Goetze J. The Posttranslational Phase of Gene Expression: New
23 Possibilities in Molecular Diagnosis. *Curr Mol Med* 2005;**3**:25–38.
24
25 9
26 10 doi:10.2174/1566524033361717
27
28
29 11 18 Hunter I, Rehfeld JF, Goetze JP. Measurement of the total proANP product in
30 mammals by processing independent analysis. *J Immunol Methods*
31
32 12 2011;**370**:104–10. doi:10.1016/j.jim.2011.06.005
33
34 13
35
36
37 14 19 Solberg HE. The IFCC recommendation on estimation of reference intervals. The
38 RefVal program. *Clin Chem Lab Med* 2004;**42**:710–4.
39
40 15
41 16 doi:10.1515/CCLM.2004.121
42
43
44
45 17 20 3.5.1. RDCT. A Language and Environment for Statistical Computing. *R Found*
46 *Stat Comput* 2018;**2**:<https://www.R-project.org>.<http://www.r-project.org>
47
48 18
49
50 19 21 Chun TH, Itoh H, Ogawa Y, *et al*. Shear stress augments expression of C-type
51 natriuretic peptide and adrenomedullin. *Hypertension* 1997;**29**:1296–302.
52
53 20
54
55 21 doi:10.1161/01.HYP.29.6.1296
56
57
58
59
60

- 1
2
3 1 22 Zhang Z, Xiao Z, Diamond SL. Shear Stress Induction of C-type Natriuretic
4
5 2 Peptide (CNP) in Endothelial Cells is Independent of NO Autocrine Signaling. *Ann*
6
7 *Biomed Eng* 1999;**27**:419–26. doi:10.1114/1.203
8
9
10
11 4 23 Prickett TCR, Olney RC, Cameron VA, *et al.* Impact of age, phenotype and
12
13 5 cardio-renal function on plasma C-type and B-type natriuretic peptide forms in an
14
15 6 adult population. *Clin Endocrinol (Oxf)* 2013;**78**:783–9. doi:10.1111/cen.12035
16
17
18 7 24 Barber DA, Burnett JC, Fitzpatrick LA, *et al.* Gender and relaxation to C-type
19
20 8 natriuretic peptide in porcine coronary arteries. *J Cardiovasc Pharmacol*
21
22 9 1998;**32**:5–11. doi:10.1097/00005344-199807000-00002
23
24
25
26 10 25 Prickett TCR, Barrell GK, Wellby M, *et al.* Effect of sex steroids on plasma C-type
27
28 11 natriuretic peptide forms: Stimulation by oestradiol in lambs and adult sheep. *J*
29
30 12 *Endocrinol* 2008;**199**:481–7. doi:10.1677/JOE-08-0267
31
32
33
34 13 26 Moyes AJ, Chu SM, Aubdool AA, *et al.* C-type natriuretic peptide co-ordinates
35
36 14 cardiac structure and function. *Eur Heart J* 2020;**41**:1006–20.
37
38 15 doi:10.1093/eurheartj/ehz093
39
40
41
42 16 27 Vitale C, Mendelsohn ME, Rosano GMC. Gender differences in the
43
44 17 cardiovascular effect of sex hormones. *Nat Rev Cardiol* 2009;**6**:532–42.
45
46 18 doi:10.1038/nrcardio.2009.105
47
48
49
50 19 28 Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender
51
52 20 differences. *Science (80-)* 2005;**308**:1583–7. doi:10.1126/science.1112062
53
54
55 21 29 Den Ruijter HM, Haitjema S, Asselbergs FW, *et al.* Sex matters to the heart: A
56
57
58
59
60

1
2
3 1 special issue dedicated to the impact of sex related differences of cardiovascular
4
5 2 diseases. *Atherosclerosis* 2015;**241**:205–7.

6
7
8 3 doi:10.1016/j.atherosclerosis.2015.05.003

9
10
11 4 30 Palmer SC, Prickett TCR, Espiner EA, *et al.* Regional release and clearance of C-
12
13 5 type natriuretic peptides in the human circulation and relation to cardiac function.

14
15 6 *Hypertension* 2009;**54**:612–8. doi:10.1161/HYPERTENSIONAHA.109.135608
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Sex-specific characteristics, medical history, and biochemical results in groups of proCNP concentrations in the STEMI-cohort.

	All patients (n = 1755)			Females (n = 466)			Males (n = 1289)		
	Normal proCNP	Increased proCNP	P Value	Normal proCNP	Increased proCNP	P Value	Normal proCNP	Increased proCNP	P Value
Number, n (%)	1472 (83.6)	283 (16.1)	-	385 (81.9)	81 (17.2)	-	1087 (84.2)	202 (15.6)	-
Age, years	63 (54-72)	66 (56-76)	.046	67 (56-77)	72 (60-80)	.16	62 (53-70)	64 (55-74)	.21
Males, n (%)	1087 (73.8)	202 (71.4)	.42	-	-	-	-	-	-
Height, cm	-	-	-	165 (160-169)	164 (160-168)	.13	178 (173-182)	178 (174-183)	.87
BMI, kg/m²	26.3 (24.1-29.3)	26.3 (23.8-30.1)	.96	25.4 (20.0-29.1)	25.7 (22.5-31.2)	.61	26.5 (24.5-29.3)	26.5 (24.2-29.9)	.76
Smoking, n (%)	1045 (73.3)	203 (74.9)	.60	250 (68.1)	54 (70.1)	.79	795 (75.1)	149 (76.8)	.65
Time from symptom to blood sample, min	190 (128-376)	178 (125-292)	.34	210 (136-460)	216 (141-349)	>.99	185 (125-356)	167 (123-271)	.18
LVEF, %	45 (40-55)	45 (35-55)	.33	50 (40-55)	45 (35-55)	.62	45 (40-55)	45 (36-55)	.36
Medical history, n (%)									
Hypertension	612 (42.6)	156 (56.1)	<.001	177 (46.9)	52 (65.8)	.003	435 (41.0)	104 (52.3)	.004
Diabetes mellitus	177 (12.3)	51 (18.3)	.009	47 (12.5)	18 (22.2)	.022	130 (12.2)	33 (16.5)	.11
Peripheral artery disease	72 (5.0)	24 (8.5)	.023	15 (4.0)	11 (13.6)	.002	57 (5.3)	13 (6.4)	.50
Stroke	91 (6.3)	30 (10.6)	.015	30 (7.9)	8 (9.9)	.51	61 (5.7)	22 (10.9)	.012
Chronic kidney disease	41 (2.8)	40 (14.1)	<.001	10 (2.6)	11 (13.6)	<.001	31 (2.9)	29 (14.4)	<.001
Ischemic heart disease	218 (14.8)	43 (16.3)	.53	44 (11.5)	10 (12.3)	.85	174 (16.0)	36 (17.9)	.53
Heart failure	38 (2.6)	13 (4.6)	.079	6 (1.6)	3 (3.7)	.19	32 (2.9)	10 (5.0)	.13
Biochemical analyses									
Acute Troponin I, ng/L	220 (53-1576)	323 (86-887)	.52	293 (54-3220)	813 (176-1814)	.57	188 (53-1481)	211 (58-844)	.99
Acute Troponin T, ng/L	1610 (329-3940)	953 (222-3370)	.018	1520 (394-3540)	571 (166-2753)	.076	1640 (287-4058)	1250 (242-3710)	.24
Peak Troponin I, ng/L	20264 (3413-50000)	19981 (5508-50000)	.91	12970 (2734-41856)	11721 (4014-50000)	.98	24507 (3654-50000)	20575 (5771-47927)	.56
Peak Troponin T, ng/L	3110 (1230-6920)	2430 (880-8060)	.23	2520 (995-5930)	2290 (614-8123)	.55	3380 (1400-7603)	2860 (923-8075)	.23
Plasma creatinine, μmol/L	81 (70-96)	95 (80-126)	<.001	69 (59-84)	83 (63-113)	.072	85 (74-98)	97 (86-131)	<.001
Estimated glomerular filtration rate, mL/min	83 (67-95)	70 (45-85)	<.001	79 (61-93)	61 (39-86)	.095	85 (69-96)	72 (49-86)	<.001

proANP, pmol/L	822 (515-1315)	1005 (558-1742)	.005	978 (664-1504)	1382 (747-2064)	.019	758 (488-1241)	899 (508-1499)	.10
hs-CRP \geq2 mg/L, n (%) *, †	474 (65.0)	111 (63.1)	.66	117 (67.2)	34 (68.0)	>.99	357 (64.3)	77 (61.1)	.54
ST2, ng/ml	40.0 (29.1-56.8)	39.8 (30.4-59.7)	.95	35.3 (27.0-55.0)	34.8 (26.2-58.4)	.92	41.5 (30.2-57.5)	41.5 (32.1-60.0)	.95
Syndecan-1, ng/ml^b	92.3 (64.2-137.0)	103.5 (69.4-154.0)	.001	82.2 (52.5-137.3)	99.3 (61.8-140.8)	.21	94.4 (68.1-137.0)	113.5 (71.6-155.1)	.019
Soluble thrombomodulin, ng/ml^b	7.35 (5.98-8.91)	8.49 (6.67-10.86)	<.001	6.71 (5.42-8.15)	8.05 (6.16-10.80)	.001	7.57 (6.19-9.18)	8.53 (6.70-10.87)	.003
Follow-up, n (%)									
Number of deaths within one year	114 (7.7%)	35 (12.4%)	.014	37 (9.6%)	19 (23.5%)	.001	77 (7.1%)	16 (7.9%)	.66
Cardiogenic shock	122 (8.3%)	34 (12.0%)	.052	32 (8.3%)	15 (18.5%)	.013	90 (8.3%)	19 (9.4%)	.58
Cardiac arrest coma	66 (4.5%)	19 (6.7%)	.13	14 (3.6%)	3 (3.7%)	>.99	52 (4.8%)	16 (7.9%)	.084

Continuous variables are given in median (inter-quartile range).

* Only patients with a time from onset of symptoms to CAG of <6 hours were included.

† Only patients admitted at RH (313 females and 873 males) were included.

Table 2. Cox regression analyses of all-cause mortality.

		Univariate			Model 1*			Model 2 †		
		HR	95% CI	P Value	HR	95% CI	P Value	HR	95% CI	P Value
All patients with proCNP ≥ median (n = 928) are included										
ProCNP (per 1 pmol/L increase)	30-day mortality	1.02	1.01-1.03	<.001	1.00	0.99-1.01	.89	1.00	0.99-1.02	.57
	1-year mortality	1.02	1.01-1.03	<.001	1.00	0.99-1.01	.89	1.00	0.99-1.02	.58
Females with proCNP ≥ median (n=260) are included										
ProCNP (per 1 pmol/L increase)	30-day mortality	1.05	1.02-1.07	<.001	1.04	1.01-1.07	.008	1.04	1.01-1.07	.016
	1-year mortality	1.04	1.02-1.07	<.001	1.03	1.01-1.06	.010	1.04	1.01-1.06	.007
Males with a proCNP ≥ median (n = 668) are included										
ProCNP (per 1 pmol/L increase)	30-day mortality	1.02	1.01-1.03	.001	1.00	0.98-1.02	.86	1.00	0.98-1.02	.92
	1-year mortality	1.02	1.01-1.03	<.001	1.00	0.98-1.01	.72	1.00	0.98-1.02	.86

All patients with a proCNP ≥ median of the sex- and age-specific reference interval are included in the analyses to test the predictive value of proCNP as a continuous variable (per 1 pmol/L increase).

* Multivariable model with age and plasma creatinine included as co-variables.

† Multivariable model with age, plasma creatinine, proANP, tertiles of peak troponins, number of vessels affected, and time from onset of symptoms to blood sample included as co-variables.

1
2
3 HR, hazard ratio; CI, confidence interval.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 3: Linear mixed models of longitudinal measurements of proCNP in 287 patients with STEMI.

	<i>Univariate model</i>		<i>Multivariate model 1</i>		<i>Multivariate model 2</i>	
	Value (95% CI) / pmol/L	P Value	Value (95% CI) / pmol/L	P Value	Value (95% CI) / pmol/L	P Value
Time (per time point)	-1.3 (-2.1 – -0.5)	.001	-0.25 (-1.8 – 1.3)	.75	-0.25 (-1.8 – 1.3)	.76
Age (per year)	Variables not included		0.16 (0.02 – 0.30)	.02	0.06 (-0.08 – 0.20)	.39
Sex (effect of male sex)			4.5 (-0.6 – 9.6)	.09	4.4 (-0.28 – 9.1)	.07
Interaction of time and sex			-1.4 (-3.2 – 0.4)	.13	-1.4 (-3.2 – 0.36)	.13
Chronic kidney disease			Variables not included		19.7 (13.3 – 26.1)	<.001
Hypertension	4.5 (0.6 – 8.4)	.03				
Diabetes	-4.0 (-9.7 – 1.7)	.17				
Peripheral artery disease	-5.1 (-13.9 – 3.7)	.26				
Stroke	2.7 (-5.3 – 10.7)	.51				

The table shows the associated estimated changes in proCNP concentration in pmol/L (95%CI) when each variable is entered in a linear mixed model. All variables included in the models are shown in the table.

CI, confidence interval.

1
2
3 **Figure 1. Study design.**
4

5
6 STEMI, ST-elevation myocardial infarction; CAG, coronary angiography; proCNP, pro-C-type natriuretic peptide (see
7
8 *Nomenclature*).
9


10
11
12
13
14
15 **Figure 2. Mortality rates for increased and normal proCNP in all patients and stratified by sex.**
16

17
18 Display of all-cause mortality rates for groups of normal vs. increased proCNP concentrations in plasma. Graphs of 30-
19
20 day and one-year mortality rate for all patients are shown in section A and B, respectively. Sex-specific 30-day and one-
21
22 year mortality rates are shown in section C and D, respectively. The numbers of patients at risk in subgroups are given
23
24 beneath each graph.
25
26
27
28
29
30



31 **Figure 3. Longitudinal concentrations of proCNP in plasma.**
32

33
34 Concentrations are shown as mean (point) and standard error of the mean (error bars). ProCNP concentrations over time
35
36 for 287 patients with STEMI are shown in section A. In section B, C, and D, these patients are grouped based on sex,
37
38 hypertension, and chronic kidney disease, respectively.
39
40
41
42
43
44
45
46
47

STUDY DESIGN



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41





— Patients with increased proCNP
— Patients with normal proCNP

No. at risk

Patients with normal proCNP	1472	1426	1412	1400	1394	1391	1387
Patients with increased proCNP	283	267	261	259	258	258	256

1472	1381	1374	1369	1363	1359	1355	1347
283	253	253	249	248	246	245	244




— Females with increased proCNP
— Females with normal proCNP
- - Males with increased proCNP
- - Males with normal proCNP

No. at risk

Females with normal proCNP	385	366	364	361	360	360	360
Females with increased proCNP	81	71	69	68	68	68	68
Males with normal proCNP	1087	1060	1048	1039	1034	1029	1027
Males with increased proCNP	202	196	192	191	190	190	188


385	357	354	354	352	351	351	346
81	67	67	64	63	62	62	62
1087	1024	1020	1015	1011	1008	1004	1001
202	186	186	185	185	184	183	182

A




BMJ Open


B



C



D



Supplemental Material

2 METHODS

3 COHORT OF PATIENTS WITH STEMI

4 Information on age, sex, height, body mass index (BMI), smoking status, development of
5 cardiogenic shock, and cardiac arrest coma, time from onset of symptoms to blood sample,
6 time from blood sample to percutaneous coronary intervention balloon angioplasty, number of
7 coronary vessels affected (defined as the number coronary arteries with at least one stenosis
8 of >70% of the lumen diameter (discrete values of zero to three) from the coronary
9 angiography procedure (CAG)), culprit coronary vessel anatomy, Thrombolysis In Myocardial
10 Infarction (TIMI) grade flow, medical history, left ventricular ejection fraction (LVEF), and
11 routine laboratory measurements was used in the data analyses. Blood samples for baseline
12 biochemical measurements were collected from the femoral or radial sheath on admission
13 immediately before CAG was performed. LVEF was determined by 2D echocardiography
14 performed on admission or within 48 hours of admission. From a consecutive subgroup of the
15 cohort, we collected repeated venous plasma samples during the first days after admission
16 from January to March 2016 at Rigshospitalet (RH) for longitudinal assessment of potential
17 changes in proCNP concentrations. Longitudinal plasma samples were collected at least
18 twice within the first day of admission, and once daily in subsequent days of admission. All
19 patients with longitudinal plasma samples are included in the analyses.

20 BIOCHEMICAL ANALYSES

1
2
3
4 1 Troponin T was measured in patients admitted to RH by Elecsys Troponin T hs assay
5
6 2 (Cobas, by Roche, Basel, Switzerland), whereas troponin I was measured in patients
7
8
9 3 admitted to Odense Universitetshospital (OUH) using Architect *STAT* High Sensitive
10
11 4 Troponin-I (Abbott, Chicago, Illinois, United States). Both measurements from samples on
12
13 5 admission and measured peak values during admission (the latter as a proxy of myocardial
14
15 6 infarction size), were used in our statistical analyses. Plasma creatinine was measured using
16
17 7 CREP2 assay and high sensitivity C-reactive protein (hs-CRP) using CRPHS assay (Cobas,
18
19 8 by Roche, Basel, Switzerland). ST2 was measured by Presage ST2 Assay (Critical
20
21 9 Diagnostics, Inc., San Diego, California). We included measurement of soluble
22
23 10 thrombomodulin (sTM) and syndecan-1 as markers of endothelial cell and glycocalyx
24
25 11 damage, respectively. Assay procedures of sTM and syndecan-1 have been described
26
27 12 previously.[1] With regards to measurement of hs-CRP, the results were analyzed as the
28
29 13 proportion of patients with a concentration of ≥ 2 mg/L. This cut-off value has been introduced
30
31 14 as a definition of chronic inflammation in cardiac disease.[2] Moreover, patients with a time
32
33 15 from onset of symptoms to blood sample of ≥ 6 hours are excluded from hs-CRP analyses
34
35 16 because an increase in hs-CRP concentration can be expected due to myocardial
36
37 17 damage.[3,4] For measurement of syndecan-1, sTM, and hs-CRP, only patients admitted at
38
39 18 RH were analyzed. All biochemical analytes, apart from peak troponins and longitudinal
40
41 19 proCNP and proANP, were measured in blood samples collected on admission.
42
43
44
45
46
47
48
49 20
50
51

52 21 **RESULTS**

53
54
55
56
57
58
59
60


1 PROCNP MEASUREMENT

2 Coefficients of variation of proCNP measurement in plasma were 13.8% for 20 pmol/L and
3 13.1% for 40 pmol/L.

4 REFERENCE POPULATION AND STEMI COHORT

5 By inspection of histograms of proCNP concentrations, we concluded that there were no
6 outliers among the individuals. Table 1 shows sex- and age-specific 95% reference intervals
7 of proCNP concentrations in the reference population. Plasma concentrations in males were
8 marginally higher compared to those in females ($P = 0.015$). Women ≥ 50 years had higher
9 proCNP concentrations compared to women < 50 years ($P = 0.011$), where no difference was
10 observed among men ($P = 0.44$). A flowchart of the inclusion of patients is shown in
11 Supplemental Figure 1. The distributions of proCNP concentrations in the reference
12 population and the STEMI cohort are shown in Supplemental Figure 2.

13 **Supplemental Figure 1: Flowchart of the inclusion of patients in study**



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental Table 1. Reference intervals of proCNP in sex- and age-specific groups.

Age groups (years)	Men		Women	
	<50	≥50	<50	≥50
Number of subjects	157	173	179	179
95% reference interval	10.2 – 52.2	13.9 – 49.6	13.6 – 48.9	13.4 – 49.4
Median	35.2	36.0	32.2	34.6


Range	4.4 – 55.4	11.4 – 52.4	8.2 – 55.4	4.4 – 60.0
-------	------------	-------------	------------	------------

1 Reference intervals, median, and range of proCNP concentrations of subgroups are all given

2 in pmol/L.

For peer review only

1
2
3
4 **1 Supplemental Figure 2. Histograms of relative frequencies of plasma proCNP**
5
6
7 **2 concentrations.**
8
9



3
4 The reference population is represented by blue bars and the STEMI cohort by red bars.

5 Each bar represents an interval of 5 pmol/L.

6 Values of >85 pmol/L are not shown.

7
8 **Information from coronary angiography**

1
2
3
4 1 In Supplemental Table 2 data from coronary angiography on culprit vessel, numbers of
5
6 2 coronary vessels affected and Thrombolysis in Myocardial Infarction (TIMI) grade flow is
7
8
9 3 shown in all patients and sex-specifically.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Supplemental Table 2. Culprit vessel, number of coronary vessels affected and Thrombolysis in Myocardial Infarction grade flow.

	All patients (n = 1755)			Females (n = 466)			Males (n = 1289)		
	Normal proCNP	Increased proCNP	P Value	Normal proCNP	Increased proCNP	P Value	Normal proCNP	Increased proCNP	P Value
Culprit vessel									
None, n (%)	55 (3.7)	7 (2.5)	.38	21 (5.5)	5 (6.2)	.79	34 (3.1)	2 (1.0)	.10
Left main coronary artery, n (%)	31 (2.1)	5 (1.8)	>.99	15 (3.9)	2 (2.5)	.75	16 (1.5)	3 (1.5)	>.99
Left anterior descending coronary artery, n (%)	623 (42.3)	119 (42.0)	.95	144 (37.4)	31 (38.3)	.90	479 (44.1)	88 (43.6)	.94
Right coronary artery, n (%)	529 (35.9)	115 (40.6)	.14	148 (38.4)	34 (42.0)	.62	381 (35.1)	81 (40.1)	.18
Left circumflex, n (%)	221 (15.0)	36 (12.7)	.36	54 (14.0)	9 (11.1)	.59	167 (15.4)	27 (13.4)	.52
Graft, n (%)	10 (0.7)	1 (0.4)	>.99	1 (0.3)	0 (0)	>.99	9 (0.8)	1 (0.5)	>.99
Number of vessels affected									
No-vessel disease, n (%)	29 (2.0)	2 (0.7)	.21	14 (3.6)	2 (2.5)	>.99	15 (1.4)	0 (0)	.15
One-vessel disease, n (%)	903 (61.5)	172 (60.7)	.84	243 (63.4)	46 (56.8)	.31	660 (60.8)	126 (62.4)	.70
Two-vessels disease, n (%)	333 (22.7)	61 (21.6)	.76	75 (19.6)	20 (24.7)	.29	258 (23.8)	41 (20.3)	.32
Three-vessels disease, n (%)	204 (13.9)	48 (17.0)	.20	51 (13.3)	13 (16.0)	.48	153 (14.1)	35 (17.3)	.23
Thrombolysis in Myocardial Infarction (TIMI) grade flow									
0, n (%)	96 (6.8)	21 (7.4)	.60	28 (7.2)	8 (9.9)	.49	68 (6.3)	13 (6.4)	.88
1, n (%)	6 (0.4)	1 (0.4)	>.99	1 (0.3)	0 (0)	>.99	5 (0.5)	1 (0.5)	>.99
2, n (%)	49 (3.3)	7 (2.5)	.58	17 (4.4)	2 (2.5)	.55	32 (2.9)	5 (2.5)	>.99
3, n (%)	1321 (89.7)	254 (89.8)	>.99	339 (88.1)	71 (87.7)	.85	982 (90.3)	183 (90.6)	>.99


Cardiogenic shock development and cardiac arrest

When median proCNP concentrations were tested in patients with cardiogenic shock development vs. no cardiogenic shock development and cardiac arrest coma vs. no cardiac arrest coma or cardiogenic shock development, no differences were observed ($P = 0.41$ and $P = 0.28$ for females, respectively, and $P = 0.97$ and $P = 0.46$ for males, respectively).

Time from onset of symptoms to blood sample and correlation of biochemical markers

In Supplemental Figure 3, median plasma proCNP concentrations are shown in subgroups of different time intervals from onset of symptoms to blood sample. A difference in proCNP was observed across subgroups ($P < 0.001$). However, when patients with a time interval of >24 hours were excluded, no difference was found ($P = 0.091$). Information on time from baseline blood sampling (performed when the CAG procedure was initiated) to percutaneous coronary intervention balloon angioplasty (time of reperfusion) was obtained on 862 patients (227 women, 635 men). Median (interquartile range) values in minutes were: 5 (4-9) and 5 (3-9) ($P = 0.90$) for women with normal and increased proCNP respectively, and 6 (4-10) and 5 (4-10) ($P = 0.17$) for men with normal and increased proCNP respectively. For biochemical markers with positive associations to proCNP, we performed Spearman's correlation analyses, and for proCNP vs. creatinine, proANP, syndecan-1, and sTM, Spearman r were 0.26, 0.082, 0.098, and 0.24, respectively ($P < 0.001$ for all).

1
2
3
4 **1 Supplemental Figure 3: Box-plots of proCNP concentrations in groups of time from**
5
6 **2 onset of symptoms to admission.**
7
8
9



3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3
4 Boxes indicate median and inter-quartile range, and error bars indicate the interval from 2.5 to
5 97.5 percentile.

6 **Sensitivity and specificity of increased proCNP and one-year mortality**

7 For one-year mortality, the sensitivity (defined as the proportion of patients that died, who had
8 increased proCNP) vs. specificity (defined as the proportion of patients that survived, who had
9 normal proCNP) were 34% vs. 85% for females and 17% vs. 84% for males.


10 **Multivariable Cox regression analyses**

1
2
3
4 1 We examined the effect of proCNP concentrations as a continuous variable on the hazard
5
6 2 ratio (HR) of one-year all-cause death in all patients as well as females and males separately
7
8
9 3 by cubic spline plots, using median concentrations as a reference point (shown in
10
11 4 Supplemental Figure 4). In females, there was no effect of proCNP below median
12
13 5 concentrations, whereas the estimated HR increased from approximately median
14
15 6 concentrations to the highest measured concentrations. In males, a trend towards a U-shaped
16
17 7 relation was observed with increasing estimated hazard ratios for decreases of proCNP below
18
19 8 median and for increases of proCNP above median. Based on these observations we focused
20
21 9 our Cox regression analyses on the upper range of proCNP, where we observed that
22
23 10 increasing proCNP was associated with increasing HR in both females and males.
24
25
26
27
28
29
30

31 12 **Supplemental Figure 4: Cubic spline and density plots of hazard ratio and proCNP**
32
33 13 **concentrations.**
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Hazard ratio and density of proCNP in all patients with STEMI




1

Smooth HR and density of proCNP in women with STEMI



2



1

2

3

4 Longitudinal plasma measurements

5 In Supplemental Table 3, the number of patients and samples in groups stratified according to
6 diseases are shown. Longitudinal measurements of proANP are shown in Supplemental
7 Figure 5, where the initial decrease from first (0 hours) to second (1-12 hours) timepoint is
8 estimated to be ~850 pmol/L (~85%).

9

10 **Supplemental Table 3: Number of patients and plasma samples in longitudinal**
11 **analyses.**

12

13

14

15

16

17


18

19

20

	Number of patients (females/males)	Number of samples (from females/from males)
Overall	287 (64/223)	907 (211/696)
Chronic kidney disease	26 (6/20)	81 (20/61)
Hypertension	131 (32/99)	412 (96/316)
Diabetes	34 (8/26)	107 (20/87)
Stroke	15 (5/10)	46 (16/30)
Peripheral artery disease	12 (2/10)	40 (6/34)

1
2
3
4 **1 Supplemental Figure 5: Longitudinal concentrations of proANP in plasma.**
5
6
7



2
3 Concentrations are shown as mean (SEM) for patients with longitudinal plasma samples.

4 **DISCUSSION**

5 *Assay Principle*

6 Our proCNP radioimmunoassay is developed in accordance with a processing-independent
7 principle,[5,6] where different fragments of the prohormone of CNP can be accurately
8 quantitated in circulation regardless of post-translational processing of the prohormone. Also,
9 there is no cross-reactivity to the structurally related cardiac natriuretic propeptides.[7]

1 *Reference Intervals*

2 We based our calculated 95% reference intervals on two age groups of < and \geq 50 years. The
3 reason for choosing this division is a previous report showing that NT-proCNP concentrations
4 in plasma in healthy individuals increase from \sim 50 years of age.[8] We therefore assume that
5 the two age groups represent two different stages of adulthood with regard to circulating NT-
6 proCNP concentrations and, hence, that the two age-specific intervals (for each sex)
7 constitute a meaningful reference for interpretation of measured proCNP concentrations in the
8 STEMI cohort.

9 *Time from onset of symptoms to blood sampling and balloon angioplasty*

10 In our baseline and multivariable Cox regressions analyses we have included the time from
11 onset of symptoms as a variable, where we have data from the 99.5% of the included
12 patients. Our results on time from blood sampling to balloon angioplasty (data was obtained
13 from 49.1% of the included patients) show no differences in time between groups of normal
14 and increased proCNP in both sexes, where the median time duration was 5-6 minutes in all
15 groups. Assuming that the total ischemic time of the STEMI patients is equal to the time from
16 onset of symptoms to balloon angioplasty (time of reperfusion), our analyses support that the
17 time onset of symptoms to blood sampling as a variable also reflects the total ischemic time of
18 the patients.

19 *Correlation Analyses of Biochemical Measurements*

20 Correlation analyses showed that the association of proCNP with sTM is superior in
21 comparison to both that of syndecan-1 and proANP. A likely explanation may be that both

1
2
3
4 1 proCNP and sTM are released from endothelial cells, whereas the glycocalyx and the
5
6 2 cardiomyocytes are the major sources of syndecan-1 and proANP, respectively. In contrast to
7
8 the vascular markers, however, no associations with markers of inflammation, hs-CRP, and
9 3
10 ST2 were observed. Thus, proCNP concentrations in plasma do not seem to be affected by
11 4
12
13 5 general inflammation in patients with STEMI.
14
15

16 6 *Longitudinal Analyses*

17
18
19 7 Repeated measurements displayed a statistically significant decrease in proCNP
20 8
21 concentrations over time in a univariate analysis. For comparison we have included repeated
22 9
23 measurements of proANP, shown in Supplemental Figure 5. The dynamic response of
24 10
25 proANP differs markedly from proCNP with a steep decrease from 0 to 1-12 hours and a flat
26 11
27 curve from 1-12 to >24 hours. These differences highlight the distinct biological roles of CNP
28 12
29 vs. ANP.
30
31
32
33

34 13 For proCNP, both multivariate linear mixed models (Model 1 and 2) show that the effect of
35 14
36 time was reduced in magnitude and was non-significant, indicating that changes over time are
37 15
38 better explained by other variables than time per se. Model 1 found an independent effect of
39 16
40 age with higher concentrations of proCNP per year, but Model 2 found that the effect of age
41 17
42 disappeared when chronic kidney disease and other vascular diseases were included. Thus,
43 18
44 age per se does not seem to explain an increase in proCNP concentration; more likely,
45 19
46 chronic diseases (where prevalence increases with age) appear a confounder of the crude
47 20
48 effect of age. Although a statistically insignificant finding, Model 1 indicates an effect of male
49 21
50 sex and an interaction of sex and time that are unchanged after inclusion of chronic diseases
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 in Model 2. Consistent with the effect of male sex are previously reported results[8] and the
2 results of the reference population of the present study, where males have slightly higher
3 concentrations of proCNP-derived peptides in the circulation. The possible interaction of sex
4 and time, where males display a relative decrease over time compared with females, has not
5 previously been reported. However, our longitudinal analyses lack the statistical power to
6 sufficiently conclude on a potential interaction of sex and time on proCNP concentrations. In
7 model 2, we find that chronic kidney disease and hypertension are independently associated
8 with higher proCNP concentrations, consistent with baseline associations.

9 Of the (cardio)vascular diseases with a crude positive association to increased proCNP in
10 baseline results, only hypertension is statistically independent in the multivariate repeated
11 measurement analysis. Unexpectedly, the independent effects of diabetes mellitus and
12 peripheral artery disease seem to be oppositely directed, where the diseases are
13 independently associated with lower proCNP concentrations. However, these results were
14 statistically insignificant, and further studies with more statistical power are needed to
15 determine if such negative independent associations exist.

16

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 (Oxf) 2013;**78**:783–9. doi:10.1111/cen.12035

2

For peer review only

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1 3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	7-8
Objectives	3	State specific objectives, including any prespecified hypotheses	7-8
Methods			
Study design	4	Present key elements of study design early in the paper	8-12
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8-11
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	8-10
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8-11 + suppl.
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10 + suppl.
Bias	9	Describe any efforts to address potential sources of bias	-
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10-11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	10-12 + suppl.
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	12-15 + table 1-2 + figure 1 +suppl
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12-15 + table 1-2 + figure 1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		(b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	+suppl
Outcome data	15*	Report numbers of outcome events or summary measures over time	table 2 + figure 1

For peer review only

1 2 3 4 5 6 7 8 9 10 11	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	12-15 + table 1-2 + figure 1 +suppl
12 13 14 15 16 17 18	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12-15 + table 1-2 + figure 1-2 +suppl
19	Discussion			
20	Key results	18	Summarise key results with reference to study objectives	15-19
21 22 23	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18
24 25	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15-19
26 27	Generalisability	21	Discuss the generalisability (external validity) of the study results	15-18
28	Other information			
29 30 31 32	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.